Previous Article in Journal
Rationally Designed Molecularly Imprinted Polymer Electrochemical Biosensor with Graphene Oxide Interface for Selective Detection of Matrix Metalloproteinase-8 (MMP-8)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering

by
Nicolas M. Brunet
1,
Peng Xiong
2 and
Prescott Bryant Chase
3,*
1
Department of Psychology, California State University, San Bernardino, CA 92407, USA
2
Department of Physics, Florida State University, Tallahassee, FL 32306, USA
3
Department of Biological Science, Florida State University, Tallahassee, FL 32306, USA
*
Author to whom correspondence should be addressed.
Biosensors 2025, 15(10), 672; https://doi.org/10.3390/bios15100672 (registering DOI)
Submission received: 30 August 2025 / Revised: 30 September 2025 / Accepted: 2 October 2025 / Published: 4 October 2025
(This article belongs to the Special Issue Biosensors for Personalized Treatment)

Abstract

The actomyosin complex—nature’s dynamic engine composed of actin filaments and myosin motors—is emerging as a versatile tool for bio-integrated nanotechnology. This review explores the growing potential of actomyosin-powered systems in biosensing and actuation applications, highlighting their compatibility with physiological conditions, responsiveness to biochemical and physical cues and modular adaptability. We begin with a comparative overview of natural and synthetic nanomachines, positioning actomyosin as a uniquely scalable and biocompatible platform. We then discuss experimental advances in controlling actomyosin activity through ATP, calcium, heat, light and electric fields, as well as their integration into in vitro motility assays, soft robotics and neural interface systems. Emphasis is placed on longstanding efforts to harness actomyosin as a biosensing element—capable of converting chemical or environmental signals into measurable mechanical or electrical outputs that can be used to provide valuable clinical and basic science information such as functional consequences of disease-associated genetic variants in cardiovascular genes. We also highlight engineering challenges such as stability, spatial control and upscaling, and examine speculative future directions, including emotion-responsive nanodevices. By bridging cell biology and bioengineering, actomyosin-based systems offer promising avenues for real-time sensing, diagnostics and therapeutic feedback in next-generation biosensors.

1. Introduction

Over the past few decades, the idea of building machines at the scale of molecules—nanotechnology—has evolved from science fiction into a vibrant and fast-growing scientific and engineering field [1]. The use of biologically inspired and natural molecular machines is thus being explored in areas as diverse as medicine, biology, chemistry and materials science. Foundational visions of the field emphasized the potential of nanoscale machinery and self-assembly [1,2,3,4], providing a conceptual framework that continues to inspire both synthetic and biologically inspired nanodevices.
Whether naturally occurring or engineered, nanomachines are extremely small systems designed to convert energy into motion. They can be powered by chemical reactions, light, heat, or electrical inputs and are often capable of performing tasks autonomously or semi-independently. Their potential in medicine is especially exciting, offering possibilities for:
(1)
Delivering drugs to precise locations in the body.
(2)
Monitoring physiological signals through molecular-scale sensors
(3)
Detecting diseases through tiny sensors.
(4)
Stimulating or repairing parts of the nervous system.
(5)
Transporting materials inside cells.
(6)
Performing microsurgery.
(7)
Aiding in tissue healing and regeneration.
These diverse opportunities are summarized in Figure 1, which highlights the broad biomedical applications where actomyosin-powered nanodevices may play a transformative role.
Of these, biosensing has emerged as a particularly promising frontier: biological systems can be used not only as targets of detection but also as active components in the sensing process itself. The fusion of mechanical responsiveness, biochemical sensitivity and nanoscale scalability opens new opportunities for biosensors that are both precise and biologically integratable [5,6,7,8].
This review begins with an overview of different types of nanomachines, including both biological and synthetic examples. It then focuses on one of biology’s most powerful and adaptable molecular motor systems: actomyosin. Found in muscle cells and across a wide range of other cell types, actomyosin combines strength, energetic efficiency, responsiveness and biocompatibility—making it especially promising for nanotechnological applications in areas including cardiovascular and neural health.
Biomolecular motors—including actomyosin—can power nanoscale transport, sorting, and sensing systems [9,10,11]. In the context of biosensing, actomyosin systems provide dynamic and reversible mechanical responses to biochemical stimuli such as ATP, calcium and pH—making them ideal candidates for developing responsive sensors that operate in physiologically relevant environments. These properties enable applications where actomyosin-powered structures can both detect and respond to biochemical cues, forming the basis of integrated sensing and actuation platforms. A recent and technically detailed review [12] focuses on actomyosin-based nanodevices, particularly in vitro motility assays and surface chemistry. The present paper complements this work by offering a broader, multidisciplinary synthesis—placing actomyosin in the wider context of biosensing, soft robotics and neuromorphic interfaces.
By bridging insights from cell biology, bioengineering and applied nanoscience, this paper highlights how actomyosin systems—powered by nature and refined by design—may serve as the basis for a new generation of smart, adaptable and biologically integrated nanodevices.

2. Nanotechnology at the Molecular Scale

Nanotechnology is not just one thing—it includes a wide range of tools and machines that work at incredibly small scales. Some are inspired by biology; others are designed from scratch in the lab. Table 1 provides a summary overview of the different categories of nanomachine-based devices that are being developed and the targeted applications in medicine and biology.

2.1. Rotary Enzymes

Some natural enzymes, such as mitochondrial ATP synthase [13,14,15,16] and bacterial flagellar motors [17,18,19,20,21], rotate as they carry out their biological functions. These naturally occurring nanomotors [17,20,21,22,23] have been adapted for use in engineered nanosystems. Enzyme-powered nanomotors (EMNMs), powered by diverse biochemical reactions, can be applied in tasks like targeted drug delivery, molecular sensing, or environmental cleanup [24]. However, the reliance of EMNMs on fuels that are not biocompatible—such as hydrogen peroxide—limits their potential for use inside the human body [25,26,27].

2.2. DNA Walkers

These machines use specially designed strands of DNA to “walk” along tiny tracks [8,28,29]. They are very precise and programmable, and can be used for tasks like detecting disease markers or releasing drugs at specific sites. Their main drawback is that they move slowly and need a tightly controlled environment to work properly.

2.3. Synthetic Molecular Motors

These are built entirely in the lab and can be triggered by light, chemicals, or other inputs [30]. They are used in “smart” materials that can change shape or function in response to their surroundings. But since they often require conditions not found inside the body, using them in living systems can be challenging [30,31,32,33,34].

2.4. Stimuli-Responsive Polymers

These materials undergo physical or chemical changes when exposed to specific triggers such as heat, light, or shifts in acidity. In medical contexts, they offer promise for targeted drug release or as components in artificial muscles. Despite their versatility, they still face technical challenges in achieving tissue specificity and maintaining stability in complex biological environments [35,36,37,38].

2.5. Nanoparticles

Particles made of gold, magnetic materials, or fluorescent compounds are used for imaging, targeted treatment and heating cancer cells [39,40,41,42,43]. Though useful, some can be toxic or hard for the body to remove.
Each of the technologies described above offer unique advantages but also come with limitations. This has motivated a growing interest in biological systems that already perform reliably within the human body—such as the actomyosin motor complex.

3. Molecular Motors and Their Tracks

Nature has developed effective nanoscale transport systems over millions of years. Within cells, motor proteins travel along filament networks to move cargo, assist in cell division, and maintain cellular structure with remarkable precision [44,45]. These biological mechanisms now serve as inspiration for the design of synthetic nanotechnology platforms.

3.1. Molecular Motor Types

Biological molecular motors belong to large, evolutionarily conserved protein families, each comprising numerous isoforms specialized for different tasks [46]. These superfamilies—myosins, kinesins and dyneins—are encoded by dozens of genes and exhibit substantial diversity in structure, function and cellular localization [46,47,48].
Three of the best-known biological motors found in eukaryotes (summarized in Table 2) are:
Myosin, which moves along actin filaments and is the molecular motor of muscle contraction and many other types of cellular movement, is particularly well suited for nanotechnology due to its biocompatibility and tunable control mechanisms [12,49,50]. In humans alone, the myosin superfamily includes over 40 genes grouped into more than 35 classes, encompassing both conventional muscle myosins (e.g., Myosin II) and unconventional variants (e.g., Myosin V, VI, X), which differ in directionality, step size, duty ratio, cargo preference and biological function [51,52,53,54] associated with localization in cells [46,47].
Kinesin, which walks toward the outer edges of cells along structures called microtubules, transports cargo over long distances, making its use feasible for applications in nanotechnology (see Khataee and Khataee [55] for its use in nanotechnology). The kinesin superfamily includes more than 45 genes in mammals and is divided into at least 14 families based on motor domain phylogeny and function [48,56]. Some kinesins move in the opposite direction (e.g., Kinesin-14), highlighting the family’s functional versatility.
Dynein, which moves in the opposite direction of most kinesins and plays roles in cell division, transporting materials and moving cilia and flagella, has also been considered for nanotech applications [55,57]. It forms large multi-subunit assemblies and is encoded by a smaller number of genes in comparison with the kinesin and myosin families. Dynein motors are exclusively minus-end directed and fall into two main types: cytoplasmic and axonemal dyneins. Both are essential for retrograde transport and motility [58,59].
Each motor protein offers a unique combination of directionality, speed and function, making them suitable building blocks for nanoscale devices requiring controlled motion. Table 2 provides a comparative overview of their key transport properties and nanotechnological relevance for the three major families of cytoskeletal motor proteins found in eukaryotes.

3.2. Potential Uses in Nanotechnology

Potential applications include:
(1)
Transport of tiny objects, such as drug-filled, enzyme-containing, or antibody-coated vesicles, to specific locations on a surface;
(2)
Sensor-triggered, localized actuation—precise responses initiated when a molecular sensor is activated;
(3)
Sorting molecules in miniaturized lab-on-a-chip systems;
(4)
Powering devices where these proteins carry components or move fluids.
The underlying mechanics of these systems can be reproduced in vitro using purified proteins (native or recombinantly expressed) that have been positioned on structured surfaces. By adjusting variables such as motor concentration, energy availability and the surrounding environment, it becomes possible to direct movement in a predictable and controlled fashion. Additional layers of regulations, such as light responsiveness or thermal sensitivity, can be introduced to fine-tune behavior further.
While kinesin and dynein are excellent for long-range transport, it is the actomyosin system that stands out for its balance of strength, control and compatibility with the human body. Section 4 explores this system in depth.

3.3. Natural vs. Synthetic Nanomotors

Biological motors such as myosin, kinesin and dynein convert chemical energy into mechanical work with high efficiency, responsiveness to physiological cues and excellent biocompatibility [60,61,62]. These features make them well-suited for integration into diagnostic, transport and actuation systems [11]. By contrast, synthetic nanomotors—such as DNA walkers and rotaxanes—offer design flexibility and programmability but often lack force output, speed, or operation under physiological conditions [63,64,65]. As shown in Figure 2, actomyosin systems occupy a unique niche, combining biological adaptability with engineering utility—making them ideal for hybrid nanoscale devices [66].

4. The Actomyosin System as a Bio-Nanomachine

4.1. Actomyosin’s Role in the Body

The actomyosin system is one of biology’s most reliable engines. It plays a central role in muscle contraction and also more generally in how eukaryotic cells move, divide, and maintain or change their shape. At the heart of this system are two key proteins: myosin, which acts as a molecular motor, and actin, which forms the tracks it moves along. When myosin uses energy from ATP, it pulls on actin filaments, generating motion and force at the nanoscale that can be used for cellular motion including muscle contraction, intracellular transport and modulation of cell shape including during cell division [60,67].

4.1.1. Muscles: Built for Contraction

In skeletal and cardiac muscle, the actomyosin system is organized into highly regular repeating units called sarcomeres that are the reason why these muscles appear to be striated. The striations are due to thick filaments of myosin that alternate, and interdigitate with thin filaments of actin. When an electrical and/or chemical signal arrives that triggers a contraction by transiently elevating cytoplasmic Ca2+ concentration, these filaments slide past each other to shorten the sarcomere, producing force and movement [68,69,70]. This “sliding filament” model driven by actomyosin crossbridge cycling, proposed in the 1950s and refined over decades, remains a foundational concept in muscle physiology [71,72,73,74].
This sliding mechanism depends on a finely tuned regulatory system that controls when and how myosin interacts with actin. At the center of this regulation in eukaryotic striated muscles is tropomyosin and the troponin complex, which respond to changes in calcium ion (Ca2+) concentration to control access of myosin motors to binding sites on the thin filament:
(1)
Molecules of tropomyosin, an α-helical coiled-coil dimeric protein, bind “head-to-tail” to form two strands on a thin filament that block myosin motors’ access to binding sites on actin at resting levels of cytoplasmic Ca2+ (~10−7 M Ca2+).
(2)
Troponin C subunit of the troponin complex binds Ca2+ when a striated muscle is activated due to a transient increase in the cytoplasmic concentration of Ca2+ (Ca2+ transient).
(3)
Troponin I subunit holds the troponin complex together by binding both the troponin C and troponin T subunits; the C-terminus of troponin I is located between actin and tropomyosin at resting Ca2+ levels, keeping tropomyosin in position to prevent formation of actomyosin crossbridges; when cytoplasmic Ca2+ rises during a Ca2+ transient, Ca2+ binds troponin C, which allows troponin C to bind the C-terminus of troponin I, in turn allowing tropomyosin to move on the surface of actin such that actomyosin crossbridge cycling can occur.
(4)
Troponin T subunit binds the troponin complex to tropomyosin in a stoichiometry of the structural regulatory unit of 1:1:7 (troponin:tropomyosin:actin) and, due to its elongated structure, participates in communication along and between the two strands of tropomyosin on a thin filament.
Cryo-electron microscopy studies have revealed important details about how these regulatory proteins undergo structural changes in response to calcium, providing insights into their dynamic roles in contraction and relaxation [75,76,77,78,79]. When Ca2+ levels rise, the structure of the thin filament shifts with displacement of tropomyosin and unblocking of sites on actin that allow myosin to bind. As long as Ca2+ and ATP are available, the contraction continues. When Ca2+ declines, everything resets and the muscle relaxes [80,81].
Myosin itself exists in multiple conformational states, including an energy-conserving “super-relaxed” state that helps regulate metabolic efficiency during rest [82]. Understanding these states has implications for both basic biology and disease treatment [46].

4.1.2. Beyond Muscles: A Cellular Workhorse

The same actomyosin machinery operates throughout the body in non-muscle cells, where it performs a variety of essential tasks:
(1)
During cell division, actomyosin forms a contractile ring that tightens to divide one cell into two.
(2)
For cell movement, it drives the extension and retraction of structures like lamellipodia and filopodia.
(3)
In intracellular transport, especially in actin-rich environments such as neurons or epithelial layers, it helps to move organelles and vesicles.
(4)
In mechanical sensing, it allows cells to respond to tension or pressure in their environment [83].
Different myosin isoforms specialize in these tasks, offering variations in speed, strength and cargo handling. For instance, non-muscle myosin II is critical for maintaining cell shape and enabling movement and adhesion, often working in coordination with signaling pathways to modulate cellular responses [84,85].

4.1.3. Why Actomyosin Is Ideal for Nanotechnology

Actomyosin has several qualities that make it especially attractive for building nanoscale devices:
(1)
It is powered by MgATP, a natural energy source, but can also utilize other nucleotides. For example, substituting deoxyATP (dATP) for ATP has been shown to enhance both the force and velocity of actomyosin interactions. This biochemical flexibility underscores the system’s adaptability and suggests opportunities to fine-tune motor output for specialized nanotechnological tasks [86,87,88].
(2)
It responds to calcium, temperature and pH, offering built-in control.
(3)
Although Ca2+ is the primary physiological regulator, other divalent cations such as Sr2+ and Ba2+ can also substitute to activate thin filaments, albeit with altered kinetics and sensitivity [89,90]. This property has been widely used experimentally and expands the biochemical flexibility of the system.
(4)
It operates with remarkable efficiency, with theoretical estimates suggesting that up to 50% of chemical energy can be converted into mechanical work under optimal conditions [91].
(5)
It exerts force at the piconewton level and enables motion at the nanometer scale, but organizes function across micrometer-scale cellular structures.
(6)
It is reversible and durable, capable of repeating its cycle over and over.
These properties—summarized visually in Figure 3—position actomyosin as an ideal platform for biohybrid tools that combine biological precision with engineered versatility. Altogether, this system offers a rare combination of precision, reliability and bio-compatibility—making it a standout candidate for driving future nanotechnological tools.

4.2. Recreating Actomyosin Function in the Laboratory

Over the past two decades, researchers have successfully recreated the actomyosin system outside of living cells, paving the way for innovations in nanobiotechnology. These engineered setups, known collectively as in vitro motility assays, provide a controlled environment to observe and manipulate the interaction between actin filaments and myosin motors—forming the basis for biologically powered microdevices [92,93,94,95].
There are two main experimental designs commonly used:
(1)
Gliding assays, where myosin motors are immobilized on a surface (typically glass or plastic), and actin filaments (typically fluorescently labeled) are allowed to glide across in the presence of ATP [96]. These setups are ideal for studying motor performance—such as speed and processivity—and for screening the effects of drugs or genetic mutations, especially in cardiac or skeletal muscle proteins.
(2)
Bead assays, in which actin filaments are tethered in place while myosin-coated beads are introduced to mimic cargo transport [95,97]. These designs help to measure force generation and enable the development of systems for directional transport and targeted delivery.
As reviewed extensively by Månsson [12], myosin-based gliding assays have been optimized for surface interaction and filament stability. This review focuses on how these systems are now evolving beyond fundamental research. As illustrated in Figure 3A, these core assay formats serve as modular starting points for applications in actuation, biosensing, drug delivery and molecular transport [24]. The growing availability of purified protein components, combined with microfabrication techniques, has enabled the integration of actomyosin assays into larger platforms for medical diagnostics, drug delivery and responsive soft materials. In practice, these systems are often assembled from a mix of native and recombinant proteins: actin and myosin are typically purified from skeletal or cardiac tissue to ensure functional integrity [93,98,99], whereas regulatory proteins such as tropomyosin and troponin are more readily produced recombinantly and combined with actin filaments to create regulated, Ca2+-sensitive thin filaments [100,101,102]. Myosin fragments with functional motor domains (e.g., heavy meromyosin or subfragment-1) can be generated by proteolysis of purified, native myosins or, in some instances, recombinantly to facilitate surface attachment and controlled activity [93,103,104,105,106,107,108,109,110,111,112,113]. Using such combinations, reconstituted actomyosin systems have been embedded into microfluidic devices that direct cargo to specific sites or used as testbeds to study how mutations in contractile proteins alter motor function.
Importantly, these biohybrid designs not only demonstrate reliable, repeatable motion at the microscale but also offer tunable parameters—such as ATP concentration or environmental temperature—that can be customized for different use cases. Figure 3B highlights these diverse control modalities, including calcium, temperature and optical triggers—all of which contribute to programmable actomyosin performance. In summary, in vitro actomyosin assays offer more than just a window into cellular mechanics; they are increasingly serving as modular building blocks in nanotechnology. Their simplicity, versatility and compatibility with biological and synthetic components make them a powerful tool for future device development.

4.3. Controlling Actomyosin in Artificial Systems

To effectively integrate actomyosin into technological applications, external control is required to initiate, pause, or modulate its activity. In biological systems, this is handled naturally by signals that initiate and modulate cytoplasmic Ca2+ transients. In artificial environments, multiple strategies have been developed to achieve comparable precision in directing nanoscale movement.

4.3.1. Biochemical Control (ATP and Calcium Ions)

This method replicates the native mechanism by using MgATP as an energy source and calcium to regulate myosin–actin interactions. In muscle and many non-muscle cells, calcium acts as a key trigger: when intracellular Ca2+ levels rise, the troponin–tropomyosin complex undergoes a conformational shift that exposes myosin-binding sites on actin, allowing contraction to proceed. Although Ca2+ is the physiological activator, other divalent cations such as Sr2+ and Ba2+ can partially substitute in activating thin filaments, typically with altered sensitivity and kinetics. These substitutions have been used experimentally to probe regulatory mechanisms [89,90,114]. In vivo, actomyosin regulation is further influenced by neurotransmitter signaling; for example, serotonin has been shown to modulate contractility and morphogenesis across divergent lineages [115].
In vitro assays that incorporate regulated actin filaments (actin decorated with tropomyosin and troponin) allow precise control of this interaction, making them ideal for studying how Ca2+ modulates thin filament activation. In most experimental systems, actin and myosin are purified from native sources, while regulatory proteins such as troponin and tropomyosin are more readily produced recombinantly and then combined with actin filaments to confer Ca2+-dependent regulation [92,93,99,101,102,116,117]. These systems have been widely used to assess both normal regulatory function and the impact of disease-associated mutations in Ca2+-sensitive proteins. For example, gliding filament assays can quantify changes in filament sliding velocity and activation thresholds, offering insight into how specific mutations alter contractile behavior [102,118,119,120,121,122,123,124,125].
Beyond Ca2+ regulation, nucleotide identity itself can modulate performance. Substitution of ATP with dATP, for instance, increases filament sliding speed and force generation, offering a simple yet powerful means of tuning actomyosin behavior in vitro. Such approaches may allow the design of nanosystems where motor output is optimized for specific applications [86,126,127]. New kinetic models have been proposed to reinterpret how actomyosin transduces energy under varying nucleotide and regulatory conditions, offering updated frameworks for designing such nanosystems [128,129,130].
Moreover, disease-associated mutations linked to hypertrophic cardiomyopathy (HCM)—such as those in cardiac troponin I or tropomyosin—can result in altered Ca2+ sensitivity, often shifting the activation curve and modifying the energy efficiency or kinetics of contraction [121,131]. These mutant proteins have been incorporated into nanomechanical assays primarily to model disease mechanisms and to reveal how pathological variants alter Ca2+-dependent regulation compared with healthy proteins; while such studies are currently research tools, they also suggest potential for future diagnostic platforms that differentiate physiological from pathological Ca2+ responses [101,117,132,133,134].
This approach offers high biocompatibility and reversibility, as movement ceases when calcium is removed [135,136]. However, response times are relatively slow, and broad calcium signaling may inadvertently affect other biological processes within hybrid systems.
Importantly, mutant-regulated filaments could also be integrated into biosensors or smart drug-delivery devices, where their unique calcium-response profiles might enable disease-specific actuation. For example, a device that differentially responds to local Ca2+ transients in heart failure versus healthy tissue could be designed using variants with altered Ca2+ activation thresholds.

4.3.2. Thermal Control (Heat)

Localized heating—achieved using embedded microheaters or thermoresponsive surfaces—can trigger actomyosin activity within milliseconds [123,137,138,139]. Rapid activation and spatial targeting make this method attractive, especially for microdevice integration. However, assays must be conducted within a moderate thermal range: reliable Ca2+ regulation is observed between ~20–35 °C, while prolonged exposure above ~45 °C risks protein denaturation or damage to surrounding biomaterials [137].
Beyond mechanical activation, temperature can modulate the regulatory state of thin filaments, particularly those containing troponin and tropomyosin. Micropatterned heat pulses can trigger calcium-sensitive activation of cardiac thin filaments, with distinct roles played by each regulatory component [140,141]. In such assays, thin filaments are typically reconstituted from native actin and recombinant troponin/tropomyosin, allowing researchers to probe how temperature shifts modulate Ca2+-dependent regulation under controlled in vitro conditions [142,143]. These findings emphasize that the effect of heat is not limited to increased kinetic energy but includes specific molecular interactions between Ca2+-regulatory proteins.
Importantly, gliding filament assays using regulated actin have been used to study how temperature shifts modulate filament sliding. This approach enables comparison between healthy regulatory systems and variants linked to cardiomyopathy. For example, mutations in cardiac troponin T and I (e.g., R278C and R145G, respectively) can sensitize filaments to temperature changes, leading to aberrant activation even at physiologically mild heat elevations [121,131,137]. Such responses may have clinical relevance, as increased body temperature during exercise or fever could precipitate contractile dysregulation in individuals with these mutations.
This dual sensitivity to calcium and temperature provides opportunities for designing actomyosin-based devices that mimic physiological regulatory complexity—while also revealing risks for heat-induced dysfunction in disease models. Recent methodological advances have also extended the stability of actomyosin motility assays, enabling sustained function for many hours under optimized flow cell and buffer conditions [144]. Assays exploiting thermal gradients may thus serve both as diagnostic tools and as models for developing personalized therapies.

4.3.3. Electrical or Electrochemical Stimulation

The application of electrical fields can modify pH (Stewart et al., 2021), ion concentrations [145], or initiate ATP synthesis, offering compatibility with silicon-based platforms. Such methods provide fast and programmable control, although unintended cross-talk with nearby components or pH-sensitive materials may limit selectivity [146].

4.3.4. Light Activation (Optogenetics or Photothermal Methods)

Light-based systems offer non-invasive, reversible and highly localized control. For broader design principles and recent applications of photoactivated molecular motors, see Corra et al. [32]. Certain light-sensitive proteins undergo conformational changes in response to illumination, enabling control over actomyosin activity [147,148]. Photothermal nanoparticles offer an alternative route by converting light into heat, activating motors indirectly. Optogenetic tools have demonstrated precise activation of contraction in living tissue [149] and continue to show potential for expansion into fully artificial constructs [150]. In vitro, light activation is often implemented by integrating recombinant light-sensitive domains into regulatory proteins, which are then combined with native actin–myosin systems to create optically responsive constructs [151].

4.3.5. Surface Patterning and Environment Control

Motion can be shaped by tailoring the substrate. Microchannels, chemical gradients and patterned coatings can confine and steer actin filaments along desired trajectories, functioning like nanoscale tracks. While this method does not initiate or halt motion directly, it provides spatial guidance and increases transport fidelity. Often demonstrated with kinesin and microtubules [152], similar techniques are applicable to actomyosin, too. Physical constraint and optimization strategies for patterning have been reviewed [12].
In most in vitro motility assays, myosin fragments—commonly heavy meromyosin (HMM) or subfragment-1 (S1)—are immobilized onto glass, plastic, or bead surfaces to serve as anchors for actin filament transport. Immobilization can be achieved through relatively simple approaches such as nitrocellulose coating, which promotes nonspecific adsorption while preserving activity [104]. More controlled chemistries include silanization of glass surfaces or the use of biotin–streptavidin linkages to couple biotinylated proteins with high specificity [153]. These strategies ensure stable attachment while maintaining enzymatic function. Site-specific immobilization using affinity tags has been developed to improve reproducibility and control of protein orientation. His-tagged myosin fragments can be linked via Ni-NTA chemistry and SNAP-tag–based strategies allow covalent coupling to functionalized substrates with defined geometry [154]. Such advances provide greater control over motor density, orientation and spatial localization, thereby extending the utility of actomyosin systems for biosensing and nanotechnological applications.
Each of these approaches has strengths and limitations. For instance, ATP/Ca2+ regulation mirrors natural control mechanisms but may lack the temporal precision of light-based triggers. Thermal and electrical systems offer speed and integration potential but may require careful calibration. Hybrid methods—such as combining surface patterning with photothermal activation—allow for increased control, enabling motion that is both guided and responsive. Confinement and surface topography can reorganize actomyosin networks, altering transport fidelity and collective behavior [155]. Table 3 summarizes the capabilities and trade-offs of these control modalities. Together, they provide the foundation for programmable actomyosin-driven nanodevices capable of precise, reversible and scalable operation within biomedical and engineering contexts.

4.4. Applications in Biomedicine and Engineering

The actomyosin system—where myosin motors move along actin filaments—acts like a tiny conveyor belt in eukaryotic cells. It helps to move materials around, to change cell shape, to guide movement and to build tissues [156]. This movement is powered by MgATP, the cell’s energy molecule, and is highly controlled and flexible [157,158,159,160].
Building on these fundamental properties and control mechanisms, recent work has begun applying actomyosin systems directly in sensing, diagnostic and therapeutic contexts. Their unique responsiveness to physiological signals—such as Ca2+, MgATP and temperature—makes them ideal candidates for developing bio-integrated platforms that can both detect and respond to changes in their environment. In what follows, we explore how these biological motors have been reconstituted into experimental systems and progressively adapted for real-world applications, including targeted delivery, responsive actuators, soft robotics, neural interfaces and biosensors.
Several natural processes show how this system works:
(1)
During early development, cells use actomyosin to pinch and fold into complex tissue shapes [161].
(2)
In cell division, it tightens like a drawstring to divide one cell into two [162].
(3)
Large cells, like egg cells, use it to stir their contents [163].
(4)
In the ear, actomyosin helps to maintain delicate structures that let us hear [164].
Inspired by these functions, actomyosin-based systems have been successfully reconstituted in laboratory environments (see Section 3.2). When actin filaments are introduced onto specially prepared surfaces containing immobilized myosin motors, they glide across the surface in a highly organized manner [49,50,165]. These systems form the basis of programmable molecular transport platforms, enabling precise control over nanoscale motion, and can be used for:
(1)
Delivering medicine: Actin filaments can carry tiny drug packages to specific locations [11,12,166,167,168].
(2)
Sorting materials: Lab-on-a-chip devices can direct different molecules or particles to the right spot [169].
(3)
Detecting chemicals: The way actin moves can signal if certain biological substances are present [170].
These applications show how actomyosin can bridge the gap between biology and engineering—offering precise movement at the microscopic scale.

4.4.1. Bioactuators and Contractile Elements

Actomyosin has been integrated into functional components of soft robotics and engineered tissues. For instance, actomyosin-generated force has been used to drive the mechanical displacement of microscale components [171]. Similarly, soft robotic elements derived from living muscle cells have been constructed to bend and even undergo partial self-repair [172].
Because actomyosin responds predictably to biochemical cues such as calcium ions and physical stimuli like temperature, it can be triggered with a high degree of control. Moreover, it operates through repeated cycles of contraction and relaxation with minimal loss of performance over time—a feature not always matched by synthetic analogs. In certain use cases, biologically derived actuators have been shown to outperform conventional mechanical alternatives, particularly in applications requiring flexibility or biocompatibility [173].
Among the biochemical cues, calcium plays a particularly powerful and tunable role. Reconstituted thin filaments containing troponin and tropomyosin exhibit clear, threshold-like responses to calcium, allowing engineered systems to mimic cardiac or skeletal muscle behavior. Gliding filament assays have been used not only to evaluate these dynamics but also to introduce disease-linked mutations into troponin components, generating constructs with unique calcium sensitivity [121,125,137]. These reconstituted systems typically pair native actin and myosin with recombinant troponin variants, allowing direct comparison between healthy and disease-linked regulation under identical assay conditions [101,117,132]. Such filaments can be used to develop actomyosin-based actuators that are selectively triggered by disease-relevant calcium ion concentration ranges.

4.4.2. Electrically and Thermally Triggered Systems

Heat and electricity can also be used to control actomyosin motion. Tiny heaters have been used to turn movement on and off with precise timing, mimicking how muscles contract and relax. These systems responded to electrical current-induced changes in temperature that occur in less than a second [137,174]. This contrasts with or is possibly compatible with other strategies where chemical and physical cues control protein deposition and provide guidance to assembly and filament motion [168,175,176,177,178,179,180,181]. Such systems can be integrated into silicon chips—suggesting a path toward compact, programmable devices powered by biological motion [182].
Thermal control of actomyosin can be especially informative when regulated actin filaments are used, allowing the simultaneous interrogation of mechanical performance and biochemical responsiveness. For example, Ishiwata’s group has shown that heat can directly activate cardiac thin filaments in a Ca2+-dependent manner, and that both myosin and troponin-tropomyosin contribute distinctively to this thermal responsiveness [140,141]. Such systems are particularly well-suited for in vitro assays that explore subtle temperature-induced regulatory transitions.
In the context of inherited cardiac disorders, thermal assays offer a unique lens to observe how pathogenic variants alter the temperature–Ca2+ activation relationship. Variants associated with hypertrophic cardiomyopathy—such as those in α-tropomyosin [125] or troponin [121,137]—can cause thin filaments to activate abnormally at elevated temperatures, even without full calcium saturation. These effects may help to explain clinical symptoms triggered by exercise or fever, including arrhythmia or sudden cardiac events in mutation carriers.
By integrating these disease-linked regulatory proteins into thermally controlled platforms, engineers can create devices that mimic pathological conditions and serve as early detection or screening tools. In a broader sense, these findings also suggest a future in which actomyosin-powered actuators respond not only to intentional thermal input but also to physiological temperature fluctuations—making them relevant for patient-specific biosensors and biohybrid implants.

4.4.3. Biosensing Applications

Actomyosin systems are very sensitive to their environment. Changes in acidity (pH), temperature, MgATP, or calcium levels can all influence how fast actin filaments move [92,137,183,184]. For example, sliding speeds change depending on how much MgATP is present [185,186]. Filaments begin to slide only after Ca2+ levels exceed a certain threshold, making actomyosin a potential biological sensor for detecting local biochemical states [187].
These finely tuned sensitivities allow actomyosin-based systems to operate not only as mechanical components but also as signal transducers. Practically, such biosensing assays are realized by immobilizing myosin fragments on patterned surfaces and introducing fluorescently labeled actin filaments with or without recombinant regulatory proteins, so that sliding velocities or activation thresholds can be measured as direct biosensor outputs [104,188]. Beyond velocity readouts, antibody-modulated actin motility has been used to develop proof-of-principle biosensors where binding events directly halt filament movement, offering a sensitive and label-free detection mode [189]. Their movement patterns can encode environmental information, forming the basis of biosensing functions that are directly coupled to mechanical readouts. This sensitivity has been leveraged in microfluidic platforms—miniaturized systems that manipulate fluids through narrow channels. These devices can detect target compounds in real time based on how they affect filament dynamics. One method uses carbon nanotubes to monitor actin–myosin interactions without the need for fluorescent tags or dyes [170].
Magnetically tagged biosensing strategies, such as those using quantum-well micro-Hall sensors to detect single magnetic beads, offer another label-free modality that is compatible with miniaturized actomyosin devices [190,191,192,193].
By embedding actomyosin elements into integrated platforms, it becomes possible to construct hybrid biosensors that convert biochemical input into visible, mechanical, or electrical output—broadening the toolkit for diagnostic, therapeutic and environmental sensing applications.
One especially important clinical application is in cardiovascular diagnostics. Cardiac troponins—particularly troponin I and T—are released into the bloodstream following myocardial injury and are the gold-standard biomarkers for diagnosing myocardial infarction [194,195,196,197]. Current diagnostic assays often rely on antibody-based detection. However, nanoscale and label-free platforms are emerging as faster, more sensitive alternatives. For example, functionalized SnO2 nanobelt field-effect transistor (FET) sensors have been developed to detect cardiac troponin without labels, using electrical readouts that respond to molecular binding [198].
Looking forward, actomyosin-based components could complement such platforms by serving as active sensing elements that respond mechanically to the presence or concentration of troponin or to shifts in calcium levels that often accompany cardiac stress. In principle, filaments reconstituted with disease-associated variants of troponin could be used to model pathological contractile responses—offering a dual readout of presence and functional consequence.
Thus, actomyosin-driven biosensors could be adapted not only for detecting circulating cardiac biomarkers but also for mimicking physiological or pathological mechanical responses in cardiovascular tissue. This dual capability makes them promising tools for real-time monitoring, early diagnosis and possibly even therapeutic feedback control in heart disease management.

4.4.4. Vision and Neural Interfaces

Beyond mechanical functions, actomyosin contributes to key processes in the nervous system, including tissue repair and neurodevelopment. In the retina, it supports nerve regeneration; suppressing specific myosin isoforms has been shown to facilitate axon regrowth after injury [199]. Within the brain, actomyosin helps to sculpt synaptic connections and guide developing neurons as they form networks [186].
Tension generated by actomyosin has also been used to stretch synthetic membranes in a controlled way, suggesting new strategies for building soft, adaptive neural interface materials. Such systems have the potential to bridge engineered devices with fragile neural tissues—providing a foundation for future technologies such as visual prosthetics and brain–machine interfaces [200].
Together, these neural and sensory applications highlight how actomyosin systems can be harnessed not only for mechanical tasks but also for dynamic interaction with the nervous system. As research progresses, this opens the door to more speculative concepts—where actomyosin-based tools might one day interface with emotional or social cues, offering responsive, human-centered technologies. The next section explores such forward-looking possibilities.

4.4.5. Looking Ahead: Emotion-Responsive Devices

One exciting and speculative direction is the development of emotion-sensitive systems using actomyosin. These envisioned devices could detect human emotional cues—such as facial expressions—and respond with controlled mechanical or chemical outputs. For example, if a face shows sadness or stress, a rise in Ca2+ or a bit of light could activate actomyosin in the device—leading to a gentle mechanical response, or even releasing helpful molecules. In practice, the actomyosin module would not “sense” emotion directly; rather, a front-end biosensor (e.g., camera plus expression-recognition software or a wearable detecting stress-linked biomarkers) would detect the cue and generate a digital control signal that then triggers the actomyosin actuator via light or local Ca2+ delivery. This might help people with social difficulties, like those with autism, by offering supportive feedback in real time [201,202,203]. We emphasize that such systems remain conceptual and would require integration of established sensing modalities with downstream actomyosin actuation.
Although no such devices currently exist, foundational components are rapidly advancing. Recent progress in optogenetically controlled actomyosin systems—such as OptoMYPT [148], a light-activated tool that modulates cellular contractility by targeting the myosin phosphatase pathway—alongside programmable bio-motors, provides a feasible technical basis for future emotion-aware biohybrid interfaces. In parallel, functionalized SnO2 nanobelt field-effect transistor (FET) sensors illustrate how hybrid devices can already achieve real-time biochemical monitoring. These FET sensors operate by transducing binding events of cardiac biomarkers (e.g., troponin I) at their functionalized surface into electrical conductance changes [204]. In practical use, they are typically exposed to small volumes of blood or serum samples rather than placed directly on cardiac tissue, though in vitro tissue studies have also applied the same principle under controlled conditions [205]. Such technologies demonstrate the potential of biohybrid systems to serve as diagnostic or monitoring tools in heart disease management.
While still in the conceptual stage, these developments suggest that actomyosin-powered technologies may ultimately extend beyond sensing and actuation—toward emotionally intelligent systems that interact dynamically with human users in both clinical and everyday contexts.
In summary, actomyosin-powered tools are moving from the lab bench into real-world applications—from biosensors to soft robots, from nerve repair to potential emotion interfaces. These biological motors, powered by nature and controlled by science, offer exciting possibilities for the future of medicine, engineering and human–technology interaction.

4.5. Engineering Challenges and Design Considerations

While actomyosin systems hold great promise, turning them into reliable tools for nanotechnology is not simple. Several key challenges need to be addressed for these biological machines to work effectively in artificial environments.

4.5.1. Stability over Time

Proteins like actin and myosin are sensitive to environmental conditions. Factors such as heat, air exposure and shifts in chemical composition can degrade their function over time. In experimental setups, fluctuations in pH and/or inorganic phosphate (Pi) concentration [183,206,207,208,209,210,211,212,213,214,215] or oxygen levels [216] can disrupt activity and lead to system failure. To address this, several strategies have been developed—including the use of sealed enclosures, buffering agents and oxygen scavengers—to help preserve protein integrity over extended periods [170].

4.5.2. Proper Attachment and Orientation

Effective operation of actomyosin systems depends on the spatial arrangement of myosin motors. When motors are unevenly distributed or randomly oriented on a surface, actin filament movement becomes erratic or stalls. To mitigate this, surface-engineering approaches have been developed to encourage uniform attachment and maintain consistent activity over time [217].

4.5.3. Spatial Control

In biological systems, motor activity is often regulated locally through spatially confined signals. In contrast, in vitro systems tend to expose the entire surface to uniform inputs, such as ATP or calcium, which limits control over where and when movement occurs. This challenge can be addressed through the use of microscale patterning, chemical gradients, or physical channeling to guide actin filament trajectories along predefined paths—effectively creating tracks for molecular transport [175,218].

4.5.4. Scaling up

When many motors work together, cooperative phenomena and new problems can emerge. Too many motors in one area might slow things down or cause unexpected traffic jams. This is why computer simulations are useful for testing designs before building them [219]. These models help predict how motor systems will behave when scaled up to more complex devices.

4.5.5. The Path Forward

Overcoming these challenges will require combining several tools:
(1)
Better chemistry to keep proteins stable;
(2)
Advanced surfaces for guiding movement;
(3)
Smarter control systems using light, heat, or electricity;
(4)
Integration with readout mechanisms for biosensing applications;
(5)
Computer modeling to plan system-wide behavior.
As efforts move from proof-of-principle devices to field-deployable tools, actomyosin systems may increasingly support multifunctional platforms where sensing, computation and actuation are performed by a single, biologically integrated module.

5. Conclusions

The actomyosin system—nature’s versatile molecular motor—is emerging as a powerful tool for the next generation of nanotechnology and biomedical devices. Its ability to generate force and movement with high efficiency, under biocompatible conditions, gives it a distinct advantage over many synthetic systems. From drug delivery and biosensing to soft robotics and potential neural interfaces, actomyosin-powered technologies are no longer confined to the lab—they are on the cusp of real-world applications.
However, turning biological motors into reliable tools for engineering remains a complex challenge. Issues of stability, scalability and precise control must be addressed through interdisciplinary innovation—combining protein chemistry, surface science, electrical and optical engineering, and computational modeling. Recent advances in optogenetics, electrochemical control and nanoscale fabrication show that these hurdles are not insurmountable [27].
In particular, the use of actomyosin as both a mechanical engine and a responsive sensor opens new possibilities for dynamic, feedback-driven devices in diagnostics and monitoring. The system’s innate sensitivity to activating Ca2+—as well as to other activating ions such as Sr2+ or Ba2+—substrate MgATP—and alternative hydrolysable nucleotide substrates such as dATP—and products MgADP, Pi and pH makes it a natural fit for biosensing platforms that require selective, real-time readouts in biological environments. Sensitivity to MgADP can be enhanced by using buffer systems such as that found in muscles and other cells, the Lohmann reaction in which the enzyme creatine kinase catalyzes the reversible transfer of Pi from phosphocreatine (PCr) to MgADP to form MgATP (and Cr), thereby lowering MgATP levels and increasing the free energy of MgATP hydrolysis, ΔGATP [210]. Similarly, sensitivity to Pi can be enhanced by using a buffer system for Pi (“phosphate mop”) such as generation of ribose-1-phosphate (and 7-methylguanine) from the substrate 7-methylguanosine in the presence of Pi by the enzyme purine nucleoside phosphorylase [220,221], which also increases the free energy of MgATP hydrolysis, ΔGATP [210].
As summarized in Figure 4, the development of actomyosin-powered nanodevices can be envisioned as a roadmap: from near-term applications in diagnostics and biosensing, through emerging integration into bioactuators and neural interfaces, to long-term speculative possibilities such as emotion-responsive devices and adaptive implants.
As researchers continue to refine these systems and build hybrid devices that merge the biological and artificial, actomyosin stands out not only for its technical potential but also for its conceptual elegance: a reminder that the solutions to tomorrow’s technological problems may already exist within our cells. The future of nanotechnology may well lie in understanding, adapting and amplifying what evolution has already perfected.

Author Contributions

Conceptualization, N.M.B. and P.B.C.; writing—original draft preparation, N.M.B.; writing—review and editing, N.M.B., P.X. and P.B.C.; visualization, N.M.B.; project administration, P.B.C.; funding acquisition, P.B.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by U.S. National Institutes of Health NHLBI grant number 5R01HL160966 to PBC.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Drexler, K.E. Nanosystems: Molecular Machinery, Manufacturing, and Computation; John Wiley & Sons: New York, NY, USA, 1992; p. 576. [Google Scholar]
  2. Drexler, K.E. Engines of Creation: Challenges and Choices of the Last Technological Revolution; Anchor/Doubleday: New York, NY, USA, 1986; p. 320. [Google Scholar]
  3. Weiss, P.S. Nanotechnology. Molecules join the assembly line. Nature 2001, 413, 585–586. [Google Scholar] [CrossRef]
  4. Weiss, P.S. Nanotechnology: A molecular four-wheel drive. Nature 2011, 479, 187–188. [Google Scholar] [CrossRef] [PubMed]
  5. Hess, H. Toward devices powered by biomolecular motors. Science 2006, 312, 860–861. [Google Scholar] [CrossRef] [PubMed]
  6. Hess, H. Engineering applications of biomolecular motors. Annu. Rev. Biomed. Eng. 2011, 13, 429–450. [Google Scholar] [CrossRef] [PubMed]
  7. Hess, H.; Saper, G. Engineering with Biomolecular Motors. Acc. Chem. Res. 2018, 51, 3015–3022. [Google Scholar] [CrossRef]
  8. Xu, M.; Tang, D. Recent advances in DNA walker machines and their applications coupled with signal amplification strategies: A critical review. Anal. Chim. Acta 2021, 1171, 338523. [Google Scholar] [CrossRef]
  9. Dinu, C.Z.; Chrisey, D.B.; Diez, S.; Howard, J. Cellular motors for molecular manufacturing. Anat. Rec. 2007, 290, 1203–1212. [Google Scholar] [CrossRef]
  10. Hess, H.; Bachand, G.D.; Vogel, V. Powering nanodevices with biomolecular motors. Chemistry 2004, 10, 2110–2116. [Google Scholar] [CrossRef]
  11. Saper, G.; Hess, H. Synthetic Systems Powered by Biological Molecular Motors. Chem. Rev. 2020, 120, 288–309. [Google Scholar] [CrossRef]
  12. Månsson, A. The potential of myosin and actin in nanobiotechnology. J. Cell. Sci. 2023, 136, jcs261025. [Google Scholar] [CrossRef]
  13. Berg, H.C. Keeping up with the F1-ATPase. Nature 1998, 394, 324–325. [Google Scholar] [CrossRef] [PubMed]
  14. Kato-Yamada, Y.; Noji, H.; Yasuda, R.; Kinosita, K., Jr.; Yoshida, M. Direct observation of the rotation of ε subunit in F1-ATPase. J. Biol. Chem. 1998, 273, 19375–19377. [Google Scholar] [CrossRef] [PubMed]
  15. Yasuda, R.; Noji, H.; Kinosita, K., Jr.; Yoshida, M. F1-ATPase is a highly efficient molecular motor that rotates with discrete 120° steps. Cell 1998, 93, 1117–1124. [Google Scholar] [CrossRef] [PubMed]
  16. Yasuda, R.; Noji, H.; Yoshida, M.; Kinosita, K., Jr.; Itoh, H. Resolution of distinct rotational substeps by submillisecond kinetic analysis of F1-ATPase. Nature 2001, 410, 898–904. [Google Scholar] [CrossRef]
  17. Berry, R.M.; Berg, H.C. Torque generated by the flagellar motor of Escherichia coli while driven backward. Biophys. J. 1999, 76, 580–587. [Google Scholar] [CrossRef]
  18. Meister, M.; Caplan, S.R.; Berg, H.C. Dynamics of a tightly coupled mechanism for flagellar rotation. Bacterial motility, chemiosmotic coupling, protonmotive force. Biophys. J. 1989, 55, 905–914. [Google Scholar] [CrossRef]
  19. Ryu, W.S.; Berry, R.M.; Berg, H.C. Torque-generating units of the flagellar motor of Escherichia coli have a high duty ratio. Nature 2000, 403, 444–447. [Google Scholar] [CrossRef]
  20. Chen, X.; Berg, H.C. Torque-speed relationship of the flagellar rotary motor of Escherichia coli. Biophys. J. 2000, 78, 1036–1041. [Google Scholar] [CrossRef]
  21. Fung, D.C.; Berg, H.C. Powering the flagellar motor of Escherichia coli with an external voltage source. Nature 1995, 375, 809–812. [Google Scholar] [CrossRef]
  22. Berry, R.M.; Berg, H.C. Torque generated by the bacterial flagellar motor close to stall. Biophys. J. 1996, 71, 3501–3510. [Google Scholar] [CrossRef]
  23. Berry, R.M.; Turner, L.; Berg, H.C. Mechanical limits of bacterial flagellar motors probed by electrorotation. Biophys. J. 1995, 69, 280–286. [Google Scholar] [CrossRef]
  24. Zhao, J.; Wang, B.; Yan, M.; Liu, Y.; Zhao, R.; Wang, X.; Shao, T.; Li, Y.; Imran, M.; Ji, M.; et al. Progress in enzyme-powered micro/nanomotors in diagnostics and therapeutics. Bioact. Mater. 2025, 46, 555–568. [Google Scholar] [CrossRef]
  25. Hortelão, A.C.; Patiño, T.; Perez-Jiménez, A.; Blanco, À.; Sánchez, S. Enzyme-Powered Nanobots Enhance Anticancer Drug Delivery. Adv. Funct. Mater. 2018, 28, 1705086. [Google Scholar] [CrossRef]
  26. Ma, X.; Hortelão, A.C.; Patiño, T.; Sánchez, S. Enzyme Catalysis To Power Micro/Nanomachines. ACS Nano 2016, 10, 9111–9122. [Google Scholar] [CrossRef]
  27. Yuan, H.; Liu, X.; Wang, L.; Ma, X. Fundamentals and applications of enzyme powered micro/nano-motors. Bioact. Mater. 2021, 6, 1727–1749. [Google Scholar] [CrossRef]
  28. Mason, S.D.; Wang, G.A.; Yang, P.; Li, Y.; Li, F. Probing and Controlling Dynamic Interactions at Biomolecule-Nanoparticle Interfaces Using Stochastic DNA Walkers. ACS Nano 2019, 13, 8106–8113. [Google Scholar] [CrossRef] [PubMed]
  29. Yang, X.; Tang, Y.; Mason, S.D.; Chen, J.; Li, F. Enzyme-Powered Three-Dimensional DNA Nanomachine for DNA Walking, Payload Release, and Biosensing. ACS Nano 2016, 10, 2324–2330. [Google Scholar] [CrossRef] [PubMed]
  30. Fan, F.; Liu, S.; Yan, Y.; Zhang, P.; Che, K. Artificial molecular motors in biological applications. Front. Mol. Biosci. 2024, 11, 1510619. [Google Scholar] [CrossRef] [PubMed]
  31. Baroncini, M.; Silvi, S.; Credi, A. Photo- and Redox-Driven Artificial Molecular Motors. Chem. Rev. 2020, 120, 200–268. [Google Scholar] [CrossRef]
  32. Corra, S.; Curcio, M.; Credi, A. Photoactivated Artificial Molecular Motors. JACS Au 2023, 3, 1301–1313. [Google Scholar] [CrossRef]
  33. Credi, A. Artificial molecular motors powered by light. Aust. J. Chem. 2006, 59, 157–169. [Google Scholar] [CrossRef]
  34. Kassem, S.; van Leeuwen, T.; Lubbe, A.S.; Wilson, M.R.; Feringa, B.L.; Leigh, D.A. Artificial molecular motors. Chem. Soc. Rev. 2017, 46, 2592–2621. [Google Scholar] [CrossRef] [PubMed]
  35. Hoffman, A.S. Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Adv. Drug Deliv. Rev. 2013, 65, 10–16. [Google Scholar] [CrossRef] [PubMed]
  36. Rao, N.V.; Ko, H.; Lee, J.; Park, J.H. Recent Progress and Advances in Stimuli-Responsive Polymers for Cancer Therapy. Front. Bioeng. Biotechnol. 2018, 6, 110. [Google Scholar] [CrossRef] [PubMed]
  37. Shah, R.A.; Frazar, E.M.; Hilt, J.Z. Recent developments in stimuli responsive nanomaterials and their bionanotechnology applications. Curr. Opin. Chem. Eng. 2020, 30, 103–111. [Google Scholar] [CrossRef]
  38. Shymborska, Y.; Budkowski, A.; Raczkowska, J.; Donchak, V.; Melnyk, Y.; Vasiichuk, V.; Stetsyshyn, Y. Switching it Up: The Promise of Stimuli-Responsive Polymer Systems in Biomedical Science. Chem. Rec. 2024, 24, e202300217. [Google Scholar] [CrossRef]
  39. Agasti, S.S.; Rana, S.; Park, M.-H.; Kim, C.K.; You, C.-C.; Rotello, V.M. Nanoparticles for detection and diagnosis. Adv. Drug Deliv. Rev. 2010, 62, 316–328. [Google Scholar] [CrossRef]
  40. Gobbo, O.L.; Sjaastad, K.; Radomski, M.W.; Volkov, Y.; Prina-Mello, A. Magnetic Nanoparticles in Cancer Theranostics. Theranostics 2015, 5, 1249–1263. [Google Scholar] [CrossRef]
  41. Hutter, E.; Maysinger, D. Gold nanoparticles and quantum dots for bioimaging. Microsc. Res. Tech. 2011, 74, 592–604. [Google Scholar] [CrossRef]
  42. Rarokar, N.; Yadav, S.; Saoji, S.; Bramhe, P.; Agade, R.; Gurav, S.; Khedekar, P.; Subramaniyan, V.; Wong, L.S.; Kumarasamy, V. Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement. Int. J. Pharm. X 2024, 7, 100231. [Google Scholar] [CrossRef]
  43. Wang, E.C.; Wang, A.Z. Nanoparticles and their applications in cell and molecular biology. Integr. Biol. 2014, 6, 9–26. [Google Scholar] [CrossRef]
  44. Lee, B.S.; Lee, S.C.; Holliday, L.S. Biochemistry of mechanoenzymes: Biological motors for nanotechnology. Biomed. Microdevices 2003, 5, 269–280. [Google Scholar] [CrossRef]
  45. van den Heuvel, M.G.L.; Dekker, C. Motor proteins at work for nanotechnology. Science 2007, 317, 333–336. [Google Scholar] [CrossRef] [PubMed]
  46. Trivedi, D.V.; Nag, S.; Spudich, A.; Ruppel, K.M.; Spudich, J.A. The Myosin Family of Mechanoenzymes: From Mechanisms to Therapeutic Approaches. Annu. Rev. Biochem. 2020, 89, 667–693. [Google Scholar] [CrossRef] [PubMed]
  47. Hartman, M.A.; Spudich, J.A. The myosin superfamily at a glance. J. Cell. Sci. 2012, 125, 1627–1632. [Google Scholar] [CrossRef]
  48. Hirokawa, N.; Noda, Y.; Tanaka, Y.; Niwa, S. Kinesin superfamily motor proteins and intracellular transport. Nat. Rev. Mol. Cell Biol. 2009, 10, 682–696. [Google Scholar] [CrossRef]
  49. Hajne, J.; Hanson, K.L.; van Zalinge, H.; Nicolau, D.V. Motility of actin filaments on micro-contact printed myosin patterns. IEEE Trans. Nanobioscience 2015, 14, 313–322. [Google Scholar] [CrossRef]
  50. Månsson, A. Translational actomyosin research: Fundamental insights and applications hand in hand. J. Muscle Res. Cell Motil. 2012, 33, 219–233. [Google Scholar] [CrossRef]
  51. de Lanerolle, P. Nuclear actin and myosins at a glance. J. Cell Sci. 2012, 125 Pt 21, 4945–4949. [Google Scholar] [CrossRef]
  52. de Lanerolle, P.; Serebryannyy, L. Nuclear actin and myosins: Life without filaments. Nat. Cell Biol. 2011, 13, 1282–1288. [Google Scholar] [CrossRef]
  53. Pestic-Dragovich, L.; Stojiljkovic, L.; Philimonenko, A.A.; Nowak, G.; Ke, Y.; Settlage, R.E.; Shabanowitz, J.; Hunt, D.F.; Hozak, P.; de Lanerolle, P. A myosin I isoform in the nucleus. Science 2000, 290, 337–341. [Google Scholar] [CrossRef]
  54. Philimonenko, V.V.; Zhao, J.; Iben, S.; Dingova, H.; Kysela, K.; Kahle, M.; Zentgraf, H.; Hofmann, W.A.; de Lanerolle, P.; Hozak, P.; et al. Nuclear actin and myosin I are required for RNA polymerase I transcription. Nat. Cell Biol. 2004, 6, 1165–1172. [Google Scholar] [CrossRef]
  55. Khataee, H.R.; Khataee, A.R. Kinesin and Dynein Smart Nanomotors: Towards Bio-Nanorobotic Systems. Nano 2010, 5, 13–23. [Google Scholar] [CrossRef]
  56. Miki, H.; Okada, Y.; Hirokawa, N. Analysis of the kinesin superfamily: Insights into structure and function. Trends Cell Biol. 2005, 15, 467–476. [Google Scholar] [CrossRef] [PubMed]
  57. Furuta, A.; Amino, M.; Yoshio, M.; Oiwa, K.; Kojima, H.; Furuta, K. Creating biomolecular motors based on dynein and actin-binding proteins. Nat. Nanotechnol. 2017, 12, 233–237. [Google Scholar] [CrossRef] [PubMed]
  58. Höök, P.; Vallee, R.B. The dynein family at a glance. J. Cell Sci. 2006, 119, 4369–4371. [Google Scholar] [CrossRef] [PubMed]
  59. Roberts, A.J.; Kon, T.; Knight, P.J.; Sutoh, K.; Burgess, S.A. Functions and mechanics of dynein motor proteins. Nat. Rev. Mol. Cell Biol. 2013, 14, 713–726. [Google Scholar] [CrossRef]
  60. Howard, J. Mechanics of Motor Proteins and the Cytoskeleton; Sinaur Associates: Sunderland, MA, USA, 2001; p. 367. [Google Scholar]
  61. Howard, J. Molecular motors: Structural adaptations to cellular functions. Nature 1997, 389, 561–567. [Google Scholar] [CrossRef]
  62. Vale, R.D. The molecular motor toolbox for intracellular transport. Cell 2003, 112, 467–480. [Google Scholar] [CrossRef]
  63. Bath, J.; Turberfield, A.J. DNA nanomachines. Nat. Nanotechnol. 2007, 2, 275–284. [Google Scholar] [CrossRef]
  64. Erbas-Cakmak, S.; Leigh, D.A.; McTernan, C.T.; Nussbaumer, A.L. Artificial Molecular Machines. Chem. Rev. 2015, 115, 10081–10206. [Google Scholar] [CrossRef]
  65. Kay, E.R.; Leigh, D.A.; Zerbetto, F. Synthetic molecular motors and mechanical machines. Angew. Chem. Int. Ed. 2007, 46, 72–191. [Google Scholar] [CrossRef]
  66. Hess, H.; Bachand, G.D. Biomolecular motors. Mater. Today 2005, 8, 22–29. [Google Scholar] [CrossRef]
  67. Pollard, T.D.; Cooper, J.A. Actin, a central player in cell shape and movement. Science 2009, 326, 1208–1212. [Google Scholar] [CrossRef] [PubMed]
  68. Gordon, A.M.; Huxley, A.F.; Julian, F.J. The variation in isometric tension with sarcomere length in vertebrate muscle fibres. J. Physiol. 1966, 184, 170–192. [Google Scholar] [CrossRef] [PubMed]
  69. Huxley, A.F.; Niedergerke, R. Structural changes in muscle during contraction. Interference microscopy of living muscle fibres. Nature 1954, 173, 971–973. [Google Scholar] [CrossRef] [PubMed]
  70. Huxley, H.; Hanson, J. Changes in the cross-striations of muscle during contraction and stretch and their structural interpretation. Nature 1954, 173, 973–976. [Google Scholar] [CrossRef]
  71. Cooke, R. The sliding filament model: 1972–2004. J. Gen. Physiol. 2004, 123, 643–656. [Google Scholar] [CrossRef]
  72. Huxley, A.F. Muscle structure and theories of contraction. Prog. Biophys. Biophys. Chem. 1957, 7, 255–318. [Google Scholar] [CrossRef]
  73. Huxley, H.E. The mechanism of muscular contraction. Science 1969, 164, 1356–1366. [Google Scholar] [CrossRef]
  74. Spudich, J.A. The myosin swinging cross-bridge model. Nat. Rev. Mol. Cell Biol. 2001, 2, 387–392. [Google Scholar] [CrossRef] [PubMed]
  75. Yamada, Y.; Namba, K.; Fujii, T. Cardiac muscle thin filament structures reveal calcium regulatory mechanism. Nat. Commun. 2020, 11, 153. [Google Scholar] [CrossRef] [PubMed]
  76. Oda, T.; Yanagisawa, H.; Wakabayashi, T. Cryo-EM structures of cardiac thin filaments reveal the 3D architecture of troponin. J. Struct. Biol. 2020, 209, 107450. [Google Scholar] [CrossRef] [PubMed]
  77. Risi, C.M.; Pepper, I.; Belknap, B.; Landim-Vieira, M.; White, H.D.; Dryden, K.; Pinto, J.R.; Chase, P.B.; Galkin, V.E. The Structure of the Native Cardiac Thin Filament at Systolic Ca2+ Levels. Proc. Natl. Acad. Sci. USA 2021, 118, e2024288118. [Google Scholar] [CrossRef]
  78. Risi, C.M.; Belknap, B.; Atherton, J.; Coscarella, I.L.; White, H.D.; Chase, P.B.; Pinto, J.R.; Galkin, V.E. Troponin structural dynamics in the native cardiac thin filament revealed by cryo electron microscopy. J. Mol. Biol. 2024, 436, 168498. [Google Scholar] [CrossRef]
  79. Risi, C.M.; Landim-Vieira, M.; Belknap, B.; Chase, P.B.; Pinto, J.R.; Galkin, V.E. The role of the troponin T interactions with actin in regulation of cardiac thin filament revealed by the troponin T pathogenic variant Ile79Asn. J. Mol. Cell. Cardiol. 2025, 204, 55–67. [Google Scholar] [CrossRef]
  80. Ebashi, S.; Endo, M. Calcium ion and muscle contraction. Prog. Biophys. Mol. Biol. 1968, 18, 123–183. [Google Scholar] [CrossRef]
  81. Lehman, W.; Craig, R. Tropomyosin and the steric mechanism of muscle regulation. Adv. Exp. Med. Biol. 2008, 644, 95–109. [Google Scholar] [CrossRef]
  82. Wilson, C.; Naber, N.; Cooke, R. The role of the super-relaxed state of myosin in human metabolism. Metabol. Open 2021, 9, 100068. [Google Scholar] [CrossRef]
  83. Chugh, P.; Paluch, E.K. The actin cortex at a glance. J. Cell Sci. 2018, 131, jcs186254. [Google Scholar] [CrossRef]
  84. Munjal, A.; Lecuit, T. Actomyosin networks and tissue morphogenesis. Development 2014, 141, 1789–1793. [Google Scholar] [CrossRef]
  85. Vicente-Manzanares, M.; Ma, X.; Adelstein, R.S.; Horwitz, A.R. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol. 2009, 10, 778–790. [Google Scholar] [CrossRef]
  86. Regnier, M.; Rivera, A.J.; Chen, Y.; Chase, P.B. 2-deoxy-ATP enhances contractility of rat cardiac muscle. Circ. Res. 2000, 86, 1211–1217. [Google Scholar] [CrossRef] [PubMed]
  87. Regnier, M.; Lee, D.M.; Homsher, E. ATP analogs and muscle contraction: Mechanics and kinetics of nucleoside triphosphate binding and hydrolysis. Biophys. J. 1998, 74, 3044–3058. [Google Scholar] [CrossRef] [PubMed]
  88. Regnier, M.; Homsher, E. The effect of ATP analogs on posthydrolytic and force development steps in skinned skeletal muscle fibers. Biophys. J. 1998, 74, 3059–3071. [Google Scholar] [CrossRef] [PubMed]
  89. Moisescu, D.G.; Thieleczek, R. Calcium and strontium concentration changes within skinned muscle preparations following a change in the external bathing solution. J. Physiol. 1978, 275, 241–262. [Google Scholar] [CrossRef]
  90. Stephenson, D.G.; Williams, D.A. Activation of skinned arthropod muscle fibres by Ca2+ and Sr2+. J. Muscle Res. Cell Motil. 1980, 1, 73–87. [Google Scholar] [CrossRef]
  91. Vilfan, A.; Šarlah, A. Theoretical efficiency limits and speed-efficiency trade-off in myosin motors. PLoS Comput. Biol. 2023, 19, e1011310. [Google Scholar] [CrossRef]
  92. Gordon, A.M.; LaMadrid, M.; Chen, Y.; Luo, Z.; Chase, P.B. Calcium regulation of skeletal muscle thin filament motility in vitro. Biophys. J. 1997, 72, 1295–1307. [Google Scholar] [CrossRef]
  93. Kron, S.J.; Toyoshima, Y.Y.; Uyeda, T.Q.P.; Spudich, J.A. Assays for actin sliding movement over myosin-coated surfaces. Methods Enzymol. 1991, 196, 399–416. [Google Scholar] [CrossRef]
  94. Murrell, M.; Thoresen, T.; Gardel, M. Reconstitution of contractile actomyosin arrays. Methods Enzymol. 2014, 540, 265–282. [Google Scholar] [CrossRef]
  95. Sheetz, M.P.; Spudich, J.A. Movement of myosin-coated fluorescent beads on actin cables in vitro. Nature 1983, 303, 31–35. [Google Scholar] [CrossRef] [PubMed]
  96. Faulstich, H.; Zobeley, S.; Rinnerthaler, G.; Small, J.V. Fluorescent phallotoxins as probes for filamentous actin. J. Muscle Res. Cell Motil. 1988, 9, 370–383. [Google Scholar] [CrossRef] [PubMed]
  97. Spudich, J.A.; Kron, S.J.; Sheetz, M.P. Movement of myosin-coated beads on oriented filaments reconstituted from purified actin. Nature 1985, 315, 584–586. [Google Scholar] [CrossRef] [PubMed]
  98. Margossian, S.S.; Lowey, S. Preparation of myosin and its subfragments from rabbit skeletal muscle. Methods Enzymol. 1982, 85, 55–71. [Google Scholar]
  99. Pardee, J.D.; Spudich, J.A. Purification of muscle actin. Methods Enzymol. 1982, 85, 164–181. [Google Scholar]
  100. Muthu, P.; Liang, J.; Schmidt, W.; Moore, J.R.; Szczesna-Cordary, D. In vitro rescue study of a malignant familial hypertrophic cardiomyopathy phenotype by pseudo-phosphorylation of myosin regulatory light chain. Arch. Biochem. Biophys. 2014, 552–553, 29–39. [Google Scholar] [CrossRef]
  101. Pinto, J.R.; Parvatiyar, M.S.; Jones, M.A.; Liang, J.; Potter, J.D. A troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin. J. Biol. Chem. 2008, 283, 2156–2166. [Google Scholar] [CrossRef]
  102. Schoffstall, B.; Brunet, N.M.; Wang, F.; Williams, S.; Barnes, A.T.; Miller, V.F.; Compton, L.A.; McFadden, L.A.; Taylor, D.W.; Dhanarajan, R.; et al. Ca2+-sensitivity of regulated cardiac thin filament sliding does not depend on myosin isoform. J. Physiol. 2006, 577 Pt 3, 935–944. [Google Scholar] [CrossRef]
  103. Sweeney, H.L.; Straceski, A.J.; Leinwand, L.A.; Tikunov, B.A.; Faust, L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J. Biol. Chem. 1994, 269, 1603–1605. [Google Scholar] [CrossRef]
  104. Kron, S.J.; Spudich, J.A. Fluorescent actin filaments move on myosin fixed to a glass surface. Proc. Natl. Acad. Sci. USA 1986, 83, 6272–6276. [Google Scholar] [CrossRef]
  105. Desai, R.; Geeves, M.A.; Kad, N.M. Using fluorescent myosin to directly visualize cooperative activation of thin filaments. J. Biol. Chem. 2015, 290, 1915–1925. [Google Scholar] [CrossRef] [PubMed]
  106. Kad, N.M.; Kim, S.; Warshaw, D.M.; Vanburen, P.; Baker, J.E. Single-myosin crossbridge interactions with actin filaments regulated by troponin-tropomyosin. Proc. Natl. Acad. Sci. USA 2005, 102, 16990–16995. [Google Scholar] [CrossRef] [PubMed]
  107. Kad, N.M.; Patlak, J.B.; Fagnant, P.M.; Trybus, K.M.; Warshaw, D.M. Mutation of a Conserved Glycine in the SH1-SH2 Helix Affects the Load-Dependent Kinetics of Myosin. Biophys. J. 2007, 92, 1623–1631. [Google Scholar] [CrossRef]
  108. Snyder, G.E.; Sakamoto, T.; Hammer, J.A., III; Sellers, J.R.; Selvin, P.R. Nanometer localization of single green fluorescent proteins: Evidence that myosin V walks hand-over-hand via telemark configuration. Biophys. J. 2004, 87, 1776–1783. [Google Scholar] [CrossRef]
  109. Sakamoto, T.; Wang, F.; Schmitz, S.; Xu, Y.; Xu, Q.; Molloy, J.E.; Veigel, C.; Sellers, J.R. Neck length and processivity of myosin V. J. Biol. Chem. 2003, 278, 29201–29207. [Google Scholar] [CrossRef]
  110. Sakamoto, T.; Yildez, A.; Selvin, P.R.; Sellers, J.R. Step-size is determined by neck length in myosin V. Biochemistry 2005, 44, 16203–16210. [Google Scholar] [CrossRef]
  111. Yang, Y.; Kovacs, M.; Sakamoto, T.; Zhang, F.; Kiehart, D.P.; Sellers, J.R. Dimerized Drosophila myosin VIIa: A processive motor. Proc. Natl. Acad. Sci. USA 2006, 103, 5746–5751. [Google Scholar] [CrossRef]
  112. Ruff, C.; Furch, M.; Brenner, B.; Manstein, D.J.; Meyhöfer, E. Single-molecule tracking of myosins with genetically engineered amplifier domains. Nat. Struct. Biol. 2001, 8, 226–229. [Google Scholar] [CrossRef]
  113. Ikezaki, K.; Komori, T.; Sugawa, M.; Arai, Y.; Nishikawa, S.; Iwane, A.H.; Yanagida, T. Simultaneous observation of the lever arm and head explains myosin VI dual function. Small 2012, 8, 3035–3040. [Google Scholar] [CrossRef]
  114. Lynch, G.S.; Stephenson, D.G.; Williams, D.A. Analysis of Ca2+ and Sr2+ activation characteristics in skinned muscle fibre preparations with different proportions of myofibrillar isoforms. J. Muscle Res. Cell Motil. 1995, 16, 65–78. [Google Scholar] [CrossRef] [PubMed]
  115. Karki, S.; Saadaoui, M.; Dunsing, V.; Kerridge, S.; Da Silva, E.; Philippe, J.-M.; Maurange, C.; Lecuit, T. Serotonin signaling regulates actomyosin contractility during morphogenesis in evolutionarily divergent lineages. Nat. Commun. 2023, 14, 5547. [Google Scholar] [CrossRef] [PubMed]
  116. Gordon, A.M.; Homsher, E.; Regnier, M. Regulation of contraction in striated muscle. Physiol. Rev. 2000, 80, 853–924. [Google Scholar] [CrossRef] [PubMed]
  117. Köhler, J.; Chen, Y.; Brenner, B.; Gordon, A.M.; Kraft, T.; Martyn, D.A.; Regnier, M.; Rivera, A.J.; Wang, C.-K.; Chase, P.B. Familial hypertrophic cardiomyopathy mutations in troponin I (K183Δ, G203S, K206Q) enhance filament sliding. Physiol. Genom. 2003, 14, 117–128. [Google Scholar] [CrossRef]
  118. Barrick, S.K.; Greenberg, L.; Greenberg, M.J. A Troponin T Variant Linked with Pediatric Dilated Cardiomyopathy Reduces the Coupling of Thin Filament Activation to Myosin and Calcium Binding. Mol. Biol. Cell 2021, 32, 1677–1689. [Google Scholar] [CrossRef]
  119. Bing, W.; Knott, A.; Redwood, C.; Esposito, G.; Purcell, I.; Watkins, H.; Marston, S. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle α-tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J. Mol. Cell. Cardiol. 2000, 32, 1489–1498. [Google Scholar] [CrossRef]
  120. Bing, W.; Redwood, C.S.; Purcell, I.F.; Esposito, G.; Watkins, H.; Marston, S.B. Effects of two hypertrophic cardiomyopathy mutations in α-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility. Biochem. Biophys. Res. Commun. 1997, 236, 760–764. [Google Scholar] [CrossRef]
  121. Brunet, N.M.; Chase, P.B.; Mihajlović, G.; Schoffstall, B. Ca2+-regulatory function of the inhibitory peptide region of cardiac troponin I is aided by the C-terminus of cardiac troponin T: Effects of familial hypertrophic cardiomyopathy mutations cTnI R145G and cTnT R278C, alone and in combination, on filament sliding. Arch. Biochem. Biophys. 2014, 552–553, 11–20. [Google Scholar] [CrossRef]
  122. Burton, D.; Abdulrazzak, H.; Knott, A.; Elliott, K.; Redwood, C.; Watkins, H.; Marston, S.; Ashley, C. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem. J. 2002, 362 Pt 2, 443–451. [Google Scholar] [CrossRef]
  123. Fraser, I.D.C.; Marston, S.B. In vitro motility analysis of actin-tropomyosin regulation by troponin and calcium: The thin filament is switched as a single cooperative unit. J. Biol. Chem. 1995, 270, 7836–7841. [Google Scholar] [CrossRef]
  124. Redwood, C.; Lohmann, K.; Bing, W.; Esposito, G.M.; Elliott, K.; Abdulrazzak, H.; Knott, A.; Purcell, I.; Marston, S.; Watkins, H. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ. Res. 2000, 86, 1146–1152. [Google Scholar] [CrossRef]
  125. Wang, F.; Brunet, N.M.; Grubich, J.R.; Bienkiewicz, E.; Asbury, T.M.; Compton, L.A.; Mihajlović, G.; Miller, V.F.; Chase, P.B. Facilitated cross-bridge interactions with thin filaments by familial hypertrophic cardiomyopathy mutations in α-tropomyosin. J. Biomed. Biotechnol. 2011, 2011, 435271. [Google Scholar] [CrossRef] [PubMed]
  126. Regnier, M.; Martyn, D.A.; Chase, P.B. Calcium regulation of tension redevelopment kinetics with 2-deoxy-ATP or low [ATP] in rabbit skeletal muscle. Biophys. J. 1998, 74, 2005–2015. [Google Scholar] [CrossRef] [PubMed]
  127. Teitgen, A.E.; Hock, M.T.; McCabe, K.J.; Childers, M.C.; Huber, G.A.; Marzban, B.; Beard, D.A.; McCammon, J.A.; Regnier, M.; McCulloch, A.D. Multiscale modeling shows how 2′-deoxy-ATP rescues ventricular function in heart failure. Proc. Natl. Acad. Sci. USA 2024, 121, e2322077121. [Google Scholar] [CrossRef] [PubMed]
  128. Månsson, A.; Usaj, M.; Moretto, L.; Matusovsky, O.; Velayuthan, L.P.; Friedman, R.; Rassier, D.E. New paradigms in actomyosin energy transduction: Critical evaluation of non-traditional models for orthophosphate release. Bioessays 2023, 45, e2300040. [Google Scholar] [CrossRef]
  129. Månsson, A. Theoretical treatment of tension transients in muscle following sudden changes in orthophosphate concentration: Implications for energy transduction. J. Muscle Res. Cell Motil. 2025, 46, 193–213. [Google Scholar] [CrossRef]
  130. Månsson, A. Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling. Front. Physiol. 2025, 16, 1576245. [Google Scholar] [CrossRef]
  131. Chase, P.B.; Brunet, N.M.; Mihajlović, G.; Xiong, P.; von Molnár, S. Molecular motor-based assays for altered nanomechanical function of Ca2+-regulatory proteins in cardiomyopathies. Mater. Res. Soc. Symp. Proc. 2008, 1096, 1096-FF02. [Google Scholar] [CrossRef]
  132. Robinson, P.; Griffiths, P.J.; Watkins, H.; Redwood, C.S. Dilated and hypertrophic cardiomyopathy mutations in troponin and a-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ. Res. 2007, 101, 1266–1273. [Google Scholar] [CrossRef]
  133. Donkervoort, S.; Papadaki, M.; de Winter, J.M.; Neu, M.B.; Kirschner, J.; Bolduc, V.; Yang, M.L.; Gibbons, M.A.; Hu, Y.; Dastgir, J.; et al. TPM3 deletions cause a hypercontractile congenital muscle stiffness phenotype. Ann. Neurol. 2015, 78, 982–994. [Google Scholar] [CrossRef]
  134. Song, W.; Dyer, E.; Stuckey, D.J.; Copeland, O.; Leung, M.C.; Bayliss, C.; Messer, A.; Wilkinson, R.; Tremoleda, J.L.; Schneider, M.D.; et al. Molecular mechanism of the E99K mutation in cardiac actin (ACTC Gene) that causes apical hypertrophy in man and mouse. J. Biol. Chem. 2011, 286, 27582–27593. [Google Scholar] [CrossRef]
  135. Harada, Y.; Noguchi, A.; Kishino, A.; Yanagida, T. Sliding movement of single actin filaments on one-headed myosin filaments. Nature 1987, 326, 805–808. [Google Scholar] [CrossRef] [PubMed]
  136. Yamashita, H.; Sata, M.; Sugiura, S.; Momomura, S.; Serizawa, T.; Iizuka, M. ADP inhibits the sliding velocity of fluorescent actin filaments on cardiac and skeletal myosins. Circ. Res. 1994, 74, 1027–1033. [Google Scholar] [CrossRef] [PubMed]
  137. Brunet, N.M.; Mihajlović, G.; Aledealat, K.; Wang, F.; Xiong, P.; von Molnár, S.; Chase, P.B. Micromechanical thermal assays of Ca2+-regulated thin-filament function and modulation by hypertrophic cardiomyopathy mutants of human cardiac troponin. J. Biomed. Biotechnol. 2012, 2012, 657523. [Google Scholar] [CrossRef]
  138. Kato, H.; Nishizaka, T.; Iga, T.; Kinosita, K., Jr.; Ishiwata, S. Imaging of thermal activation of actomyosin motors. Proc. Natl. Acad. Sci. USA 1999, 96, 9602–9606. [Google Scholar] [CrossRef]
  139. Rossi, R.; Maffei, M.; Bottinelli, R.; Canepari, M. Temperature dependence of speed of actin filaments propelled by slow and fast skeletal myosin isoforms. J. Appl. Physiol. 2005, 99, 2239–2245. [Google Scholar] [CrossRef]
  140. Ishii, S.; Oyama, K.; Arai, T.; Itoh, H.; Shintani, S.A.; Suzuki, M.; Kobirumaki-Shimozawa, F.; Terui, T.; Fukuda, N.; Ishiwata, S. Microscopic heat pulses activate cardiac thin filaments. J. Gen. Physiol. 2019, 151, 860–869. [Google Scholar] [CrossRef]
  141. Ishii, S.; Oyama, K.; Kobirumaki-Shimozawa, F.; Nakanishi, T.; Nakahara, N.; Suzuki, M.; Ishiwata, S.; Fukuda, N. Myosin and tropomyosin-troponin complementarily regulate thermal activation of muscles. J. Gen. Physiol. 2023, 155, e202313414. [Google Scholar] [CrossRef]
  142. Homsher, E.; Lee, D.M.; Morris, C.; Pavlov, D.; Tobacman, L.S. Regulation of force and unloaded sliding speed in single thin filaments: Effects of regulatory proteins and calcium. J. Physiol. 2000, 524 Pt 1, 233–243. [Google Scholar] [CrossRef]
  143. Tobacman, L.S. Thin filament-mediated regulation of cardiac contraction. Annu. Rev. Physiol. 1996, 58, 447–481. [Google Scholar] [CrossRef]
  144. Melbacke, A.; Salhotra, A.; Ušaj, M.; Månsson, A. Improved longevity of actomyosin in vitro motility assays for sustainable lab-on-a-chip applications. Sci. Rep. 2024, 14, 22768. [Google Scholar] [CrossRef]
  145. Stewart, T.J.; Murthy, V.; Dugan, S.P.; Baker, J.E. Velocity of myosin-based actin sliding depends on attachment and detachment kinetics and reaches a maximum when myosin-binding sites on actin saturate. J. Biol. Chem. 2021, 297, 101178. [Google Scholar] [CrossRef]
  146. Vemula, V.; Huber, T.; Ušaj, M.; Bugyi, B.; Månsson, A. Myosin and gelsolin cooperate in actin filament severing and actomyosin motor activity. J. Biol. Chem. 2021, 296, 100181. [Google Scholar] [CrossRef]
  147. Riveline, D.; Ott, A.; Jülicher, F.; Winkelmann, D.A.; Cardoso, O.; Lacapère, J.J.; Magnúsdóttir, S.; Viovy, J.L.; Gorre-Talini, L.; Prost, J. Acting on actin: The electric motility assay. Eur. Biophys. J. 1998, 27, 403–408. [Google Scholar] [CrossRef] [PubMed]
  148. Drozdowski, O.M.; Ziebert, F.; Schwarz, U.S. Optogenetic control of migration of contractile cells predicted by an active gel model. Commun. Phys. 2023, 6, 158. [Google Scholar] [CrossRef]
  149. Yamamoto, K.; Miura, H.; Ishida, M.; Mii, Y.; Kinoshita, N.; Takada, S.; Ueno, N.; Sawai, S.; Kondo, Y.; Aoki, K. Optogenetic relaxation of actomyosin contractility uncovers mechanistic roles of cortical tension during cytokinesis. Nat. Commun. 2021, 12, 7145. [Google Scholar] [CrossRef] [PubMed]
  150. Ganji, E.; Chan, C.S.; Ward, C.W.; Killian, M.L. Optogenetic activation of muscle contraction in vivo. Connect. Tissue Res. 2021, 62, 15–23. [Google Scholar] [CrossRef]
  151. Matsubayashi, H.T.; Razavi, S.; Rock, T.W.; Nakajima, D.; Nakamura, H.; Kramer, D.A.; Matsuura, T.; Chen, B.; Murata, S.; Nomura, S.M.; et al. Light-guided actin polymerization drives directed motility in protocells. bioRxiv 2024. [Google Scholar] [CrossRef]
  152. Yumerefendi, H.; Dickinson, D.J.; Wang, H.; Zimmerman, S.P.; Bear, J.E.; Goldstein, B.; Hahn, K.; Kuhlman, B. Control of Protein Activity and Cell Fate Specification via Light-Mediated Nuclear Translocation. PLoS ONE 2015, 10, e0128443. [Google Scholar] [CrossRef]
  153. Hiratsuka, Y.; Tada, T.; Oiwa, K.; Kanayama, T.; Uyeda, T.Q.P. Controlling the direction of kinesin-driven microtubule movements along microlithographic tracks. Biophys. J. 2001, 81, 1555–1561. [Google Scholar] [CrossRef]
  154. Sundberg, M.; Balaz, M.; Bunk, R.; Rosengren-Holmberg, J.P.; Montelius, L.; Nicholls, I.A.; Omling, P.; Tågerud, S.; Månsson, A. Selective spatial localization of actomyosin motor function by chemical surface patterning. Langmuir 2006, 22, 7302–7312. [Google Scholar] [CrossRef] [PubMed]
  155. Engin, S.; Fichtner, D.; Wedlich, D.; Fruk, L. SNAP-tag as a tool for surface immobilization. Curr. Pharm. Des. 2013, 19, 5443–5448. [Google Scholar] [CrossRef] [PubMed]
  156. Negi, A.; Sakamoto, R.; Miyazaki, M.; Maeda, Y.T. Myosin-driven advection and actin reorganization control the geometry of confined actomyosin gel. arXiv 2025, arXiv:2505.01717. [Google Scholar] [CrossRef]
  157. Murrell, M.; Oakes, P.W.; Lenz, M.; Gardel, M.L. Forcing cells into shape: The mechanics of actomyosin contractility. Nat. Rev. Mol. Cell Biol. 2015, 16, 486–498. [Google Scholar] [CrossRef]
  158. Agarwal, P.; Zaidel-Bar, R. Principles of Actomyosin Regulation In Vivo. Trends Cell Biol. 2019, 29, 150–163. [Google Scholar] [CrossRef]
  159. Okeyo, K.O.; Adachi, T.; Sunaga, J.; Hojo, M. Actomyosin contractility spatiotemporally regulates actin network dynamics in migrating cells. J. Biomech. 2009, 42, 2540–2548. [Google Scholar] [CrossRef]
  160. Semenova, I.; Burakov, A.; Berardone, N.; Zaliapin, I.; Slepchenko, B.; Svitkina, T.; Kashina, A.; Rodionov, V. Actin dynamics is essential for myosin-based transport of membrane organelles. Curr. Biol. 2008, 18, 1581–1586. [Google Scholar] [CrossRef]
  161. Titus, M.A. Myosin-Driven Intracellular Transport. Cold Spring Harb. Perspect. Biol. 2018, 10, a021972. [Google Scholar] [CrossRef]
  162. Martin, A.C.; Kaschube, M.; Wieschaus, E.F. Pulsed contractions of an actin-myosin network drive apical constriction. Nature 2009, 457, 495–499. [Google Scholar] [CrossRef]
  163. Green, R.A.; Paluch, E.; Oegema, K. Cytokinesis in animal cells. Annu. Rev. Cell Dev. Biol. 2012, 28, 29–58. [Google Scholar] [CrossRef]
  164. Fang, N.N.; Ng, A.H.; Measday, V.; Mayor, T. Hul5 HECT ubiquitin ligase plays a major role in the ubiquitylation and turnover of cytosolic misfolded proteins. Nat. Cell Biol. 2011, 13, 1344–1352. [Google Scholar] [CrossRef] [PubMed]
  165. Rzadzinska, A.K.; Schneider, M.E.; Davies, C.; Riordan, G.P.; Kachar, B. An actin molecular treadmill and myosins maintain stereocilia functional architecture and self-renewal. J. Cell Biol. 2004, 164, 887–897. [Google Scholar] [CrossRef] [PubMed]
  166. Salhotra, A.; Rahman, M.A.; Ruijgrok, P.V.; Meinecke, C.R.; Ušaj, M.; Zemsky, S.; Lindberg, F.W.; Surendiran, P.; Lyttleton, R.W.; Linke, H.; et al. Exploitation of Engineered Light-Switchable Myosin XI for Nanotechnological Applications. ACS Nano 2023, 17, 17233–17244. [Google Scholar] [CrossRef]
  167. Agarwal, A.; Hess, H. Biomolecular motors at the intersection of nanotechnology and polymer science. Prog. Polym. Sci. 2010, 35, 252–277. [Google Scholar] [CrossRef]
  168. Persson, M.; Gullberg, M.; Tolf, C.; Lindberg, A.M.; Månsson, A.; Kocer, A. Transportation of nanoscale cargoes by myosin propelled actin filaments. PLoS ONE 2013, 8, e55931. [Google Scholar] [CrossRef]
  169. Lard, M.; ten Siethoff, L.; Kumar, S.; Persson, M.; te Kronnie, G.; Linke, H.; Månsson, A. Ultrafast molecular motor driven nanoseparation and biosensing. Biosens. Bioelectron. 2013, 48, 145–152. [Google Scholar] [CrossRef]
  170. Sundberg, M.; Bunk, R.; Albet-Torres, N.; Kvennefors, A.; Persson, F.; Montelius, L.; Nicholls, I.A.; Ghatnekar-Nilsson, S.; Omling, P.; Tågerud, S.; et al. Actin filament guidance on a chip: Toward high-throughput assays and lab-on-a-chip applications. Langmuir 2006, 22, 7286–7295. [Google Scholar] [CrossRef]
  171. Miranda, M.S.; Lyttleton, R.; Siu, P.H.; Diez, S.; Linke, H.; Micolich, A.P. Prospects for single-molecule electrostatic detection in molecular motor gliding motility assays. New J. Phys. 2021, 23, 065003. [Google Scholar] [CrossRef]
  172. Yoshida, K.; Kohno, K.; Hiratsuka, Y.; Onoe, H. Macroscale Collagen-Actomyosin Hybrid Actuator Built from Bioderived Materials. Adv. Funct. Mater. 2023, 33, 2307766. [Google Scholar] [CrossRef]
  173. Heisser, R.H.; Bawa, M.; Shah, J.; Bu, A.; Raman, R. Soft Biological Actuators for Meter-Scale Homeostatic Biohybrid Robots. Chem. Rev. 2025, 125, 3976–4007. [Google Scholar] [CrossRef]
  174. Shi, M.; Yeatman, E.M. A comparative review of artificial muscles for microsystem applications. Microsyst. Nanoeng. 2021, 7, 95. [Google Scholar] [CrossRef]
  175. Mihajlović, G.; Brunet, N.M.; Trbović, J.; Xiong, P.; von Molnár, S.; Chase, P.B. All-electrical switching and control mechanism for actomyosin-powered nanoactuators. Appl. Phys. Lett. 2004, 85, 1060–1062. [Google Scholar] [CrossRef]
  176. Jaber, J.A.; Chase, P.B.; Schlenoff, J.B. Actomyosin driven motility on patterned polyelectrolyte mono- and multilayers. Nano Lett. 2003, 3, 1505–1509. [Google Scholar] [CrossRef]
  177. Huang, L.; Manandhar, P.; Byun, K.-E.; Chase, P.B.; Hong, S. Selective assembly and alignment of actin filaments with desired polarity on solid substrates. Langmuir 2006, 22, 8635–8638. [Google Scholar] [CrossRef] [PubMed]
  178. Albet-Torres, N.; O’Mahony, J.; Charlton, C.; Balaz, M.; Lisboa, P.; Aastrup, T.; Månsson, A.; Nicholls, I.A. Mode of heavy meromyosin adsorption and motor function correlated with surface hydrophobicity and charge. Langmuir 2007, 23, 11147–11156. [Google Scholar] [CrossRef]
  179. Bunk, R.; Klinth, J.; Montelius, L.; Nicholls, I.A.; Omling, P.; Tågerud, S.; Månsson, A. Actomyosin motility on nanostructured surfaces. Biochem. Biophys. Res. Commun. 2003, 301, 783–788. [Google Scholar] [CrossRef]
  180. Bunk, R.; Sundberg, M.; Månsson, A.; Nicholls, I.A.; Omling, P.; Tågerud, S.; Montelius, L. Guiding motor-propelled molecules with nanoscale precision through silanized bi-channel structures. Nanotechnology 2005, 16, 710–717. [Google Scholar] [CrossRef]
  181. Sundberg, M.; Rosengren, J.P.; Bunk, R.; Lindahl, J.; Nicholls, I.A.; Tågerud, S.; Omling, P.; Montelius, L.; Månsson, A. Silanized surfaces for in vitro studies of actomyosin function and nanotechnology applications. Anal. Biochem. 2003, 323, 127–138. [Google Scholar] [CrossRef]
  182. Lindberg, F.W.; Norrby, M.; Rahman, M.A.; Salhotra, A.; Takatsuki, H.; Jeppesen, S.; Linke, H.; Månsson, A. Controlled Surface Silanization for Actin-Myosin Based Nanodevices and Biocompatibility of New Polymer Resists. Langmuir 2018, 34, 8777–8784. [Google Scholar] [CrossRef]
  183. Grove, T.J.; Puckett, K.A.; Brunet, N.M.; Mihajlović, G.; McFadden, L.A.; Xiong, P.; von Molnár, S.; Moerland, T.S.; Chase, P.B. Packaging actomyosin-based biomolecular motor-driven devices for nanoactuator applications. IEEE Trans. Adv. Packag. 2005, 28, 556–563. [Google Scholar] [CrossRef]
  184. Debold, E.P.; Beck, S.E.; Warshaw, D.M. Effect of low pH on single skeletal muscle myosin mechanics and kinetics. Am. J. Physiol. Cell Physiol. 2008, 295, C173–C179. [Google Scholar] [CrossRef]
  185. Sich, N.M.; O’Donnell, T.J.; Coulter, S.A.; John, O.A.; Carter, M.S.; Cremo, C.R.; Baker, J.E. Effects of actin-myosin kinetics on the calcium sensitivity of regulated thin filaments. J. Biol. Chem. 2010, 285, 39150–39159. [Google Scholar] [CrossRef]
  186. Rahman, M.A.; Ušaj, M.; Rassier, D.E.; Månsson, A. Blebbistatin Effects Expose Hidden Secrets in the Force-Generating Cycle of Actin and Myosin. Biophys. J. 2018, 115, 386–397. [Google Scholar] [CrossRef] [PubMed]
  187. Turney, S.G.; Ahmed, M.; Chandrasekar, I.; Wysolmerski, R.B.; Goeckeler, Z.M.; Rioux, R.M.; Whitesides, G.M.; Bridgman, P.C. Nerve growth factor stimulates axon outgrowth through negative regulation of growth cone actomyosin restraint of microtubule advance. Mol. Biol. Cell 2016, 27, 500–517. [Google Scholar] [CrossRef] [PubMed]
  188. Homsher, E.; Kim, B.; Bobkova, A.; Tobacman, L.S. Calcium regulation of thin filament movement in an in vitro motility assay. Biophys. J. 1996, 70, 1881–1892. [Google Scholar] [CrossRef] [PubMed]
  189. Lard, M.; ten Siethoff, L.; Månsson, A.; Linke, H. Tracking actomyosin at fluorescence check points. Sci. Rep. 2013, 3, 1092. [Google Scholar] [CrossRef]
  190. Kekic, M.; Hanson, K.L.; Perumal, A.S.; Solana, G.; Rajendran, K.; Dash, S.; Nicolau, D.V., Jr.; Dobroiu, S.; Dos Remedios, C.G.; Nicolau, D.V. Biosensing using antibody-modulated motility of actin filaments on myosin-coated surfaces. Biosens. Bioelectron. 2024, 246, 115879. [Google Scholar] [CrossRef]
  191. Mihajlović, G.; Xiong, P.; von Molnár, S.; Ohtani, K.; Ohno, H.; Field, M.; Sullivan, G.J. Detection of single magnetic bead for biological applications using an InAs quantum well micro-Hall sensor. Appl. Phys. Lett. 2005, 87, 112502. [Google Scholar] [CrossRef]
  192. Aledealat, K.; Mihajlović, G.; Chen, K.-S.; Field, M.; Sullivan, G.J.; Xiong, P.; Chase, P.B.; von Molnár, S. Dynamic micro-Hall detection of superparamagnetic beads in a microfluidic channel. J. Magn. Magn. Mater. 2010, 322, L69–L72. [Google Scholar] [CrossRef]
  193. Hira, S.M.; Aledealat, K.; Chen, K.-S.; Field, M.; Sullivan, G.J.; Chase, P.B.; Xiong, P.; von Molnár, S.; Strouse, G.F. Detection of target ssDNA using a micro-fabricated Hall magnetometer with correlated optical readout. J. Biomed. Biotechnol. 2012, 2012, 492730. [Google Scholar] [CrossRef]
  194. Manandhar, P.; Chen, K.-S.; Aladealat, K.; Mihajlović, G.; Yun, C.S.; Field, M.; Sullivan, G.J.; Strouse, G.F.; Chase, P.B.; von Molnár, S.; et al. The detection of specific biomolecular interactions with micro-Hall magnetic sensors. Nanotechnology 2009, 20, 355501. [Google Scholar] [CrossRef]
  195. Labugger, R.; Organ, L.; Collier, C.; Atar, D.; Van Eyk, J.E. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000, 102, 1221–1226. [Google Scholar] [CrossRef]
  196. McGrath, S.; Alaour, B.; Kampourakis, T.; Marber, M. Cardiac Troponin: Fragments of the Future? JACC Adv. 2025, 4, 101695. [Google Scholar] [CrossRef]
  197. Salonen, S.M.; Tuominen, T.J.K.; Raiko, K.I.S.; Vasankari, T.; Aalto, R.; Hellman, T.A.; Lahtinen, S.E.; Soukka, T.; Juhani Airaksinen, K.E.; Wittfooth, S.T. Highly Sensitive Immunoassay for Long Forms of Cardiac Troponin T Using Upconversion Luminescence. Clin. Chem. 2024, 70, 1037–1045. [Google Scholar] [CrossRef]
  198. Wu, A.H.B.; Feng, Y.-J.; Moore, R.; Apple, F.S.; McPherson, P.H.; Buechler, K.F.; Bodor, G. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin. Chem. 1998, 44 Pt 1, 1198–1208. [Google Scholar] [CrossRef] [PubMed]
  199. Cheng, Y.; Chen, K.-S.; Meyer, N.L.; Yuan, J.; Hirst, L.S.; Chase, P.B.; Xiong, P. Functionalized SnO2 nanobelt field-effect transistor sensors for label-free detection of cardiac troponin. Biosens. Bioelectron. 2011, 26, 4538–4544. [Google Scholar] [CrossRef] [PubMed]
  200. Wang, X.-W.; Yang, S.-G.; Zhang, C.; Hu, M.-W.; Qian, J.; Ma, J.-J.; Zhang, Y.; Yang, B.-B.; Weng, Y.-L.; Ming, G.-L.; et al. Knocking Out Non-muscle Myosin II in Retinal Ganglion Cells Promotes Long-Distance Optic Nerve Regeneration. Cell Rep. 2020, 31, 107537. [Google Scholar] [CrossRef] [PubMed]
  201. Jahnke, K.; Maurer, S.J.; Weber, C.; Bücher, J.E.H.; Schoenit, A.; D’Este, E.; Cavalcanti-Adam, E.A.; Göpfrich, K. Actomyosin-Assisted Pulling of Lipid Nanotubes from Lipid Vesicles and Cells. Nano Lett. 2022, 22, 1145–1150. [Google Scholar] [CrossRef]
  202. Talaat, F.M.; Ali, Z.H.; Mostafa, R.R.; El-Rashidy, N. Real-time facial emotion recognition model based on kernel autoencoder and convolutional neural network for autism children. Soft. Comput. 2024, 28, 6695–6708. [Google Scholar] [CrossRef]
  203. Talaat, M.; Tayseer, M.; Farahat, M.A.; Song, D. Artificial intelligence strategies for simulating the integrated energy systems. Artif. Intell. Rev. 2024, 57, 106. [Google Scholar] [CrossRef]
  204. Hosney, R.; Talaat, F.M.; El-Gendy, E.M.; Saafan, M.M. AutYOLO-ATT: An attention-based YOLOv8 algorithm for early autism diagnosis through facial expression recognition. Neural. Comput. Appl. 2024, 36, 17199–17219. [Google Scholar] [CrossRef]
  205. Cui, Y.; Wei, Q.; Park, H.; Lieber, C.M. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001, 293, 1289–1292. [Google Scholar] [CrossRef]
  206. Iost, R.M.; Crespilho, F.N. Layer-by-layer self-assembly and electrochemistry: Applications in biosensing and bioelectronics. Biosens. Bioelectron. 2012, 31, 1–10. [Google Scholar] [CrossRef] [PubMed]
  207. Chase, P.B.; Kushmerick, M.J. Effects of pH on contraction of rabbit fast and slow skeletal muscle fibers. Biophys. J. 1988, 53, 935–946. [Google Scholar] [CrossRef] [PubMed]
  208. Pate, E.; Bhimani, M.; Franks-Skiba, K.; Cooke, R. Reduced effect of pH on skinned rabbit psoas muscle mechanics at high temperatures: Implications for fatigue. J. Physiol. 1995, 486, 689–694. [Google Scholar] [CrossRef] [PubMed]
  209. Pate, E.; Cooke, R. Addition of phosphate to active muscle fibers probes actomyosin states within the powerstroke. Pflügers Arch. 1989, 414, 73–81. [Google Scholar] [CrossRef]
  210. Cooke, R.; Franks, K.; Luciani, G.B.; Pate, E. The inhibition of rabbit skeletal muscle contraction by hydrogen ions and phosphate. J. Physiol. 1988, 395, 77–97. [Google Scholar] [CrossRef]
  211. Wiseman, R.W.; Brown, C.M.; Beck, T.W.; Brault, J.J.; Reinoso, T.R.; Shi, Y.; Chase, P.B. Creatine Kinase Equilibration and ΔGATP Over an Extended Range of Physiological Conditions: Implications for Cellular Energetics, Signaling and Muscle Performance. Int. J. Mol. Sci. 2023, 24, 13244. [Google Scholar] [CrossRef]
  212. Godt, R.E.; Nosek, T.M. Changes in intracellular milieu with fatigue or hypoxia depress contraction of skinned rabbit skeletal and cardiac muscle. J. Physiol. 1989, 412, 155–180. [Google Scholar] [CrossRef]
  213. Nosek, T.M.; Leal-Cardoso, J.H.; McLaughlin, M.; Godt, R.E. Inhibitory influence of phosphate and arsenate on contraction of skinned skeletal and cardiac muscle. Am. J. Physiol. 1990, 259 Pt 1, C933–C939. [Google Scholar] [CrossRef]
  214. Nosek, T.M.; Fender, K.Y.; Godt, R.E. It is diprotonated inorganic phosphate that depresses force in skinned skeletal muscle fibers. Science 1987, 236, 191–193. [Google Scholar] [CrossRef] [PubMed]
  215. Debold, E.P.; Romatowski, J.G.; Fitts, R.H. The depressive effect of Pi on the force-calcium relationship in skinned single muscle fibers is temperature dependent. Am. J. Physiol. Cell Physiol. 2006, 290, C1041–C1050. [Google Scholar] [CrossRef] [PubMed]
  216. Woodward, M.; Debold, E.P. Acidosis and Phosphate Directly Reduce Myosin’s Force-Generating Capacity Through Distinct Molecular Mechanisms. Front. Physiol. 2018, 9, 862. [Google Scholar] [CrossRef] [PubMed]
  217. Reisler, E. Sulfhydryl modification and labeling of myosin. Methods Enzymol. 1982, 85, 84–93. [Google Scholar] [CrossRef]
  218. Barakat, J.M.; Modica, K.J.; Lu, L.; Anujarerat, S.; Choi, K.H.; Takatori, S.C. Surface Topography Induces and Orients Nematic Swarms of Active Filaments: Considerations for Lab-On-A-Chip Devices. ACS Appl. Nano Mater. 2024, 7, 12142–12152. [Google Scholar] [CrossRef]
  219. Ishigure, Y.; Nitta, T. Simulating an Actomyosin in Vitro Motility Assay: Toward the Rational Design of Actomyosin-Based Microtransporters. IEEE Trans. Nanobioscience 2015, 14, 641–648. [Google Scholar] [CrossRef]
  220. Webb, M.R. A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc. Natl. Acad. Sci. USA 1992, 89, 4884–4887. [Google Scholar] [CrossRef]
  221. Pate, E.; Franks-Skiba, K.; Cooke, R. Depletion of phosphate in active muscle fibers probes actomyosin states within the powerstroke. Biophys. J. 1998, 74, 369–380. [Google Scholar] [CrossRef]
Figure 1. Biomedical applications of actomyosin-powered nanodevices. Biologically inspired systems (e.g., motor proteins such as myosin (green in center image) and the corresponding filaments such as actin (brown in center image) that are transported) and synthetic nanomotors are being explored for drug delivery, diagnostics, neural interfaces, microsurgery, tissue regeneration and molecular transport. Biosensing is a particularly promising near-term area, leveraging mechanical and biochemical responsiveness at the nanoscale.
Figure 1. Biomedical applications of actomyosin-powered nanodevices. Biologically inspired systems (e.g., motor proteins such as myosin (green in center image) and the corresponding filaments such as actin (brown in center image) that are transported) and synthetic nanomotors are being explored for drug delivery, diagnostics, neural interfaces, microsurgery, tissue regeneration and molecular transport. Biosensing is a particularly promising near-term area, leveraging mechanical and biochemical responsiveness at the nanoscale.
Biosensors 15 00672 g001
Figure 2. Natural vs. Synthetic Nanomotors. Comparison of key features of biological motor systems (e.g., actomyosin, kinesin and microtubules) and synthetic nanomachines (e.g., DNA walkers, rotaxanes). While synthetic systems offer programmability and modular design, biological motors provide unmatched efficiency, biocompatibility and responsiveness to physiological signals. Actomyosin stands out for its integrative potential in biomedical and hybrid nanodevice applications.
Figure 2. Natural vs. Synthetic Nanomotors. Comparison of key features of biological motor systems (e.g., actomyosin, kinesin and microtubules) and synthetic nanomachines (e.g., DNA walkers, rotaxanes). While synthetic systems offer programmability and modular design, biological motors provide unmatched efficiency, biocompatibility and responsiveness to physiological signals. Actomyosin stands out for its integrative potential in biomedical and hybrid nanodevice applications.
Biosensors 15 00672 g002
Figure 3. Actomyosin-Based Nanodevices and Their Modes of Control. (A) Overview of major applications enabled by in vitro actomyosin systems, in which actin filaments (brown filaments in both panels) glide over surface-immobilized myosin motors (green motor proteins in both panels). These biohybrid platforms support diverse functionalities—including mechanical actuation, targeted molecular transport, diagnostic assays and biosensing platforms. (B) External mechanisms for modulating actomyosin activity. Control inputs include biochemical cues (e.g., calcium ions, ATP), thermal triggers, electrical or electrochemical signals and optical stimulation. These strategies enable precise spatiotemporal regulation of motility, essential for responsive or programmable device integration.
Figure 3. Actomyosin-Based Nanodevices and Their Modes of Control. (A) Overview of major applications enabled by in vitro actomyosin systems, in which actin filaments (brown filaments in both panels) glide over surface-immobilized myosin motors (green motor proteins in both panels). These biohybrid platforms support diverse functionalities—including mechanical actuation, targeted molecular transport, diagnostic assays and biosensing platforms. (B) External mechanisms for modulating actomyosin activity. Control inputs include biochemical cues (e.g., calcium ions, ATP), thermal triggers, electrical or electrochemical signals and optical stimulation. These strategies enable precise spatiotemporal regulation of motility, essential for responsive or programmable device integration.
Biosensors 15 00672 g003
Figure 4. Roadmap for actomyosin-based nanotechnology. Near-term applications center on diagnostics and biosensing, leveraging actomyosin’s sensitivity to physiological signals. Mid-term opportunities include integration into bioactuators, soft robotics and neural interfaces, where contractile function and adaptability can be harnessed for engineered systems. Looking further ahead, speculative directions include emotion-responsive biohybrid devices, adaptive implants and human–machine symbiotic technologies. Together, these stages illustrate the trajectory from current laboratory prototypes to visionary biomedical applications.
Figure 4. Roadmap for actomyosin-based nanotechnology. Near-term applications center on diagnostics and biosensing, leveraging actomyosin’s sensitivity to physiological signals. Mid-term opportunities include integration into bioactuators, soft robotics and neural interfaces, where contractile function and adaptability can be harnessed for engineered systems. Looking further ahead, speculative directions include emotion-responsive biohybrid devices, adaptive implants and human–machine symbiotic technologies. Together, these stages illustrate the trajectory from current laboratory prototypes to visionary biomedical applications.
Biosensors 15 00672 g004
Table 1. Nanomachine classes.
Table 1. Nanomachine classes.
ClassExample(s)Actuation TriggerPotential Biomedical Applications
Natural Protein MotorsMyosin, Kinesin, DyneinATP, GTPTargeted transport, neural interfaces, synthetic muscles
Rotary EnzymesF1-ATPase, bacterial flagellaProton gradient, ATP hydrolysisBioelectronic coupling, molecular stirring/mixing
DNA-Based WalkersDNA walkers, spidersStrand displacement, enzyme fuelMolecular diagnostics, intracellular tracking
Synthetic Molecular MotorsFeringa motors, rotaxanes, catenanesLight, redox, pHDrug release, chemical computation
Stimuli-Responsive PolymersPNIPAM, polyacrylamide derivativesHeat, pH, lightDrug delivery, dynamic scaffolds
Nanoparticle SystemsMagnetic NPs, gold NPs, quantum dotsMagnetic field, lightImaging, hyperthermia, theranostics
Table 2. Natural Molecular Motors.
Table 2. Natural Molecular Motors.
Motor ProteinTrackDirectionality *Typical Step SizeVelocityPrimary FunctionNanotech Applications
MyosinActin filaments+ end (varies by isoform); − end (e.g., Myosin VI)5–36 nm~0.1–5 µm/sMuscle contraction, short-range intracellular transportBioactuators, contractile scaffolds, responsive biosensors
KinesinMicrotubules+ end (most isoforms); − end (e.g., Kinesin-14)8 nm~0.5–2 µm/sAnterograde transport (e.g., vesicles, organelles)Cargo transport on microtubule tracks, molecular sorters
DyneinMicrotubules– end8–32 nm~1–14 µm/sRetrograde transport, mitosis, ciliary and flagellar motionDirectional switches, retrograde cargo delivery, motile microsensors
* Directionality refers to the predominant behavior within each motor protein family. Notable exceptions include Myosin VI, which moves toward the minus (–) end of actin filaments, and members of the Kinesin-14 family (e.g., Kar3 in yeast, KIFC1 in mammals), which move toward the minus end of microtubules. To date, all known dyneins are minus-end directed.
Table 3. Summary of Control Modalities.
Table 3. Summary of Control Modalities.
Control MethodPrecisionReversibilityBiocompatibilityScalabilityNotes
ATP/Ca2+ RegulationModerateHighHighHighDirect physiological mimicry
Thermal ControlHighHighModerateModerateStrong for MEMS * integration
Electrical StimulationHighModerateModerateHighInterface-ready but risk of side effects
Optical/PhotothermalVery HighHighHigh (with care)ModerateAllows contact-free, localized control
Surface PatterningModerateLowHighHighIdeal for guidance, not activation
* MEMS = Microelectromechanical Systems: miniature devices that integrate mechanical and electrical components, often used in sensors, actuators, and lab-on-a-chip platforms.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Brunet, N.M.; Xiong, P.; Chase, P.B. Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering. Biosensors 2025, 15, 672. https://doi.org/10.3390/bios15100672

AMA Style

Brunet NM, Xiong P, Chase PB. Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering. Biosensors. 2025; 15(10):672. https://doi.org/10.3390/bios15100672

Chicago/Turabian Style

Brunet, Nicolas M., Peng Xiong, and Prescott Bryant Chase. 2025. "Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering" Biosensors 15, no. 10: 672. https://doi.org/10.3390/bios15100672

APA Style

Brunet, N. M., Xiong, P., & Chase, P. B. (2025). Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering. Biosensors, 15(10), 672. https://doi.org/10.3390/bios15100672

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop